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Summary 1 
1. Abstract (Summary) 
 
The endocannabinoid system has been implicated in the regulation of glial activity and 
progression of brain ageing. Mice constitutively or specifically lacking the cannabinoid receptor 
1 (CB1) on neurons or GABAergic neurons respectively have been reported to show symptoms 
of accelerated cellular and behavioural brain ageing. However, the particular cell type(s) and 
the mechanisms involved in this process have not been exhaustively elucidated. This study 
showed that inadequate regulation of immune response could be a possible phenomenon leading 
to the increased inflammation following GABA-CB1 deletion and this disturbed immune cell 
regulation becomes exacerbated in cases of chronic LPS challenge with increasing ageing. In 
addition, GABA-CB1 deletion caused enhanced accumulation of the ageing and senescence 
marker lipofuscin in isolated microglia, suggesting that microglial cells may be the major cell 
type containing the increased lipofuscin accumulation reported in hippocampal 
immunohistological staining. Moreover, a reduced 2-AG production following microglia-
specific Daglα deletion led to upregulation of immune regulator proteins which neither 
influenced cytokine production nor affected social and cognitive abilities. Furthermore, 
increased anandamide level after FAAH deletion led to increased microglia activity with age-
associated exacerbation. These findings, together, indicate that GABA-CB1 receptor-mediated 
cannabinoid signalling is crucial in the regulation of microglial activity in young as well as in 
aged animals, though the consequences of a deficient GABA-CB1 activity only become visible 
and eventually detrimental with increasing age.
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2. Introduction 
 
The endocannabinoid system (ECS) has emerged a pivotal regulator of glial activity. The role 
and implications of the ECS in the “normal” and “diseased” brain during ageing are 
increasingly of keen interest in the scientific community. Microglial cells, the resident 
immune cells of the central nervous system (CNS), play a central role in this ECS-related 
regulation of brain physiology in healthy, ageing and diseased state. 
 
2.1 Ageing and brain ageing 
 
The world report on ageing and health revealed that the majority of people across the world 
now live well beyond their 60s. This is as a result of safer childbirth and improved health care 
during childhood in developing countries, whereas in developed countries, it is rather a result 
of increasing life expectancy due to declining mortality in older individuals (World Health 
Organization, 2015). Irrespective of the specific regional and economic drivers of life 
expectancy, the common denominator is the ever-improving health care as a consequence of 
advances in medical research. Sadly but expected, increasing life expectancy also has its 
limitations and woes. Although advancement in medicine has led to increased longetivity, the 
down-side is that people now live long enough to be exposed to age-related diseases that were 
not prominent in the past when humans had a lower life expectancy. Thus, a growing concern 
in this modern society is the obvious threat posed by ageing, most specifically ageing of the 
brain with risk for neurodegeneration and cognitive impairment (Bishop, Lu and Yankner, 
2010). 
Ageing of the brain, however, occurs in individuals at varying rate, hence understanding the 
molecular mechanisms of ageing is fundamental to unravelling questions surrounding the 
process of brain ageing. Although “normal” brain ageing is not a pathological process, it shares 
some common characteristics with premature ageing diseases like in the Werner syndrome and 
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Bloom syndrome, where increasing life span is not a causative or contributing factor but 
increasing accumulation of damaged DNA. Various neurodegenerative disorders and cancers 
are also preceded by reduced integrity of molecular mechanisms akin to those observed during 
a non-pathological ageing process (Burtner and Kennedy, 2010; Lopez-Otin et al., 2013) 
 
 
 
Figure 2.1: The nine hallmarks of ageing (Lopez-Otin et al., 2013): Genomic instability, telomere 
attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial 
dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication 
 
In line with this, elucidating potential candidate hallmarks of ageing is essential to finding 
lasting solutions to age-related diseases. Over the years, research on ageing has identified quite 
a number of factors that may influence ageing.  Reviewing known molecular mechanisms that 
have been implicated in the ageing process and acknowledging that none of the candidate 
hallmarks of ageing is mutually exclusive of the other, nine hallmarks of ageing were proposed 
by Lopez-Otin et al, 2013. They further divided the candidate hallmarks into three groups; - 
The primary hallmark which includes genomic instability, telomere attrition, epigenetic 
alterations and loss of proteostasis, are all obvious causatives of cellular damage (Lopez-Otin 
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et al., 2013). Telomere attrition and genomic instability may be less detrimental in postmitotic 
cells like neurons or slowly dividing cells like microglia, whereas other more rapidly dividing 
glia cells such as oligodendrocytes and astrocytes in the CNS may be affected, leading to 
homeostatic imbalance (Miron et al., 2013). The next group was termed the antagonistic 
hallmarks. Unlike the primary hallmarks, the antagonistic hallmarks are a response to damage. 
The effect of the response depends on the intensity of damage. Hence, the resulting response 
could elicit beneficial effects at low-level damage or detrimental effects at high-level damage. 
The hallmarks belonging to this group are; deregulated nutrient sensing, mitochondrial 
dysfunction and cellular senescence. The general role of the antagonistic hallmarks is to 
mitigate the damage they are responding to. However, should the damage become chronic, this 
could trigger additional negative effects where compensatory response was intended (Lopez-
Otin et al., 2013). Senescence of the cell captures perfectly the phenomenon presented above. 
Senescence in normal physiological conditions protects the cell from being cancerous. It sets 
an internal clock for the cell after which the cell is eliminated to prevent increase in the number 
of damaged cells due to accumulation of mutations over time (Delaney et al., 2013; Soreq et 
al., 2017). But increasing senescent cells may trigger senescence in neighbouring cells through 
gap-junction-mediated cell-cell contact thereby compounding the negative effects (Lefebvre et 
al., 2012). Senescence in microglia, for instance, is especially harmful because the microglia 
do not only lose their function of clearance of debris and of other damaged cells, they further 
contribute to damaging neighbouring cells by becoming primed themselves and producing 
increasing levels of pro-inflammatory cytokines (Wynne, Henry and Godbout, 2009; Streit and 
Xue, 2014). The third category includes the integrative hallmarks. This group comprises of stem 
cell exhaustion and altered intercellular communication. They are also referred to as the culprit 
of the phenotype because they are the consequential manifestation of the effects of the two 
aforementioned categories and are responsible for the actual age-related functional decline 
(Villeda et al., 2011; Lopez-Otin et al., 2013). A declining regenerative capacity of tissues is a 
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characteristic shared by both neurodegenerative diseases and ageing (Lucin and Wyss-Coray, 
2009). This can be as a result of microglia overreactivity, leading to increased 
neuroinflammatory milieu in the brain. Ultimately, cell viability reduces in such environment 
and the end result is that otherwise healthy cells are eliminated and regeneration is hampered, 
which further compounds ageing phenotype (Wynne, Henry and Godbout, 2009). Besides stem 
cell exhaustion, altered cell-cell communication leads to imbalance and disturbed signalling. 
Altered communication between neurons and microglia is more detrimental because of the 
important role of microglia in maintaining a healthy microenvironment in the brain. 
Subsequently, the milieu becomes increasingly inflammatory thereby resulting in neurotoxicity 
(Sheridan and Murphy, 2013). 
 
2.2 Microglia in healthy, diseased and ageing brain 
 
The central nervous system [CNS] is an immune privileged organ and is largely separated from 
the peripheral immune system. Hence, blood-borne immune cells such as macrophages are 
under healthy conditions prevented from getting into the CNS. In line with this, there is a need 
for microglia, the resident immune cells of the CNS (Ousman and Kubes, 2012). Microglial 
cells are immature macrophages originating from the primitive hematopoiesis of the yolk sac 
to populate the neuroepithelium during early stages of CNS development (Ginhoux et al., 
2010). They are smaller than other glial cells and make up for about 15 % of total cell population 
in the CNS (Carson et al., 2006). Microglial cells are self-renewing, keeping their dividing 
capacity even in adulthood. On the contrary, other tissue macrophages derived from the yolk 
sac are replaced gradually by macrophages derived from monocytes of bone marrow origin. 
(Massberg et al., 2007; Hoeffel et al., 2012; Schulz et al., 2012).  
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Since the brain tissue has a restricted regenerative capacity (Zhang et al., 2007), it is highly 
sensitive to injuries and pathological conditions. Consequently, during events of brain-insults 
such as  injuries or pathological conditions, the blood brain barrier is relaxed, thus macrophages 
and other blood-borne immune cells are recruited into the CNS (Ransohoff and Cardona, 2010). 
Microglia can either be in the resting or activated state. Under healthy conditions, microglial 
cells are in the ramified state otherwise referred to as the resting state. Moreover, contrary to 
the suggestion by the term “resting”, ramified microglial cells are actually active. They survey 
their microenvironment with their long processes and are highly motile. However, if the brain 
is injured or in cases of immunological stimuli, microglial cells become activated. The now 
amoeboid-shaped microglia increase their body size and take on the role of a scavenger with 
increased reactivity (Hellwig et al., 2016). In response to a stimulus, microglia may also recruit 
blood-borne immune cells, like the T cells by presenting antigens. In addition, reactive oxygen 
species may be produced, cytokines and chemokines released and the microglia can also 
become highly phagocytic (Wynne, Henry and Godbout, 2009). Numerous publications have 
suggested that microglia/macrophages are activated to M1or M2 phenotypes. On the one hand, 
M1 polarized microglia are characterized by increased pro-inflammatory responses with mainly 
cytotoxic properties. On the other hand, M2 polarization is further divided into three activation 
states. The M2a activation state is involved in repair and regeneration, the M2b activation state 
has a mainly immunoregulatory role, while the M2c state has an acquired-deactivation property 
(Chhor et al., 2013). Yet, recent publications warn against this characterization as it is simplistic 
and no data so far have conclusively supported this classification (Ransohoff, 2016).  In order 
for microglia to respond appropriately to a cue, they express cannabinoid receptors (Palazuelos 
et al., 2009) and a wide range of other receptors that are up-regulated during various pathologies 
of the CNS (Vinet et al. 2012).  Microglia do express a functional endocannabinoid signalling 
system, which upon activation may drive certain characteristics in microglia such as 
proliferation, migration, cytokine release or a phagocytic response (Stella, 2009). Indeed, 
Introduction 7 
microglia express diacylglycerol lipases (DAGLs) and therefore can produce 2-
arachidonoylglycerol [2-AG], which has been reported to promote microglial acquisition of M2 
phenotype at least in cell culture systems (Mecha et al., 2015).  
A primary role of microglia is the immune defence thereby supporting survival of neurons and 
promoting maintenance of the microenvironment as well as other cells in the CNS. Nonetheless, 
microglial cells are increasingly being implicated as causatives or at the least contributors to 
neural damages in various neurodegenerative diseases and ageing. Accumulating evidence 
shows that microglia while responding to a stimulus may become overreactive depending on 
the strength and duration of the stimulus, causing damage to the cells they should otherwise be 
maintaining (Block, Zecca and Hong, 2007). 
 
 
Figure 2.2: Reactive microgliosis drives progressive neurotoxicity (Block, Zecca and Hong, 2007) 
 
Similarly, the risk of neurodegenerative disease has been shown to be higher with increasing 
age and there are mounting evidences that microglia play a central role in the progression of 
neurodegeneration. However, microglial cells have been reported to be more activated with 
Introduction 8 
progressing ageing and it has been shown that microglial ageing progresses in a region-
dependent manner with the hippocampus mostly affected (Grabert et al., 2016). Hence, some 
studies have hypothesized that microglial reactivity in a normal ageing process mimics that 
observed in deteriorating brains that ultimately result in neurodegenerative disorders like 
Alzheimer’s disease and Parkinson’s disease (Block, Zecca and Hong, 2007; Wyss-Coray, 
2016). 
A large number of microglia in the aged brain and in neurodegenerative diseases are primed 
and senescent (Niraula, Sheridan and Godbout, 2016). Primed microglia, also referred to as 
“sensitized” microglia are reported to have a heightened reactivity to a stimulus as compared to 
microglia that have not been previously sensitized (Jurgens and Johnson, 2012).  They damage 
the neurons in their microenvironment and then become even more activated in response to the 
damaged neurons. This process, which is termed reactive microgliosis (Block, Zecca and Hong, 
2007), leads to increased production of pro-inflammatory cytokines such as interleukin 1β (IL-
1β), interleukin 6 (IL-6) and tumour necrosis factor-α (TNF-α) but also reactive oxygen species 
(ROS) and nitric oxide (NO). The resulting toxic microenvironment now further promotes 
degeneration and age-related brain deterioration (Lucin and Wyss-Coray, 2009; Villeda et al., 
2011; Piyanova et al., 2015). 
2.3 The endocannabinoid system 
 
The plant, cannabis sativa, has remained a source of controversy in societies since its first 
recorded use dating back to over 4000 years (Murray et al., 2007). Depending on the society in 
question, the use of cannabis has been viewed as an “evil emergence” or “God’s own gift” to 
mankind. Despite this divergence in attitude, a recent World Drug Report from the United 
Nations Office on Drugs and Crime estimated that about 181 to 232 million people age 15 – 64 
use cannabis for nonmedical purposes globally (UNODC, 2015), while the acceptance of 
cannabis for medicinal use is on the rise. The main psychoactive component of this plant, Δ9-
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tetrahydrocannabinol (THC), was first isolated in 1964 (Gaoni and Mechoulam, 1964). Yet, 
only after a prolonged period of about two and a half decades was the molecular target of THC 
identified. The first target to be identified and characterized was termed cannabinoid receptor 
1 (CB1) (Devane et al., 1988), while the second to be characterized about half a decade after 
the first, was referred to as cannabinoid receptor 2 (CB2) (Munro, Thomas and Abu-Shaar, 
1993). These two receptors, their two main endogenous ligands (2-arachidonoylglycerol [2-
AG] and Anandamide [AEA]) and the synthesis and degradation enzymes of these 
endocannabinoids make up the endocannabinoid system. The endocannabinoid system (ECS) 
is a retrograde and modulatory signaling system at the synapses (Katona et al., 1999). While 
the endocannabinoids are produced on demand in the postsynapses, they are released into the 
synaptic cleft to activate cannabinoid receptors on the presynapses.  
 
Figure 2.3A: Signal transduction pathway of the cannabinoid receptors 1 and 2 activation at the 
pre-synapse (adapted from Di Marzo et al. 2004) 
 
The cannabinoid receptors 1 and 2 are members of the 7 transmembrane domain rhodopsin-like 
G-protein coupled receptors (GPCRs) that are mostly coupled to the Gi/o proteins (Dalton et al., 
A 
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2009). CB1 receptor activation leads to an inhibition of adenylate cyclase, activation of MAP 
kinases and inhibition of the calcium influx (Mackie and Hille, 1992). Consequently, 
neurotransmitter release is inhibited leading to a reduced depolarization- induced suppression 
of inhibition (DSI) or suppression of excitation (DSE) (Ohno-Shosaku, Maejima and Kano, 
2001). CB1 receptor is highly expressed in the brain with the highest density in cholecystokinin 
(CCK) positive GABAergic neurons (Lee and Soltesz, 2011; Keimpema et al., 2012). However, 
CB2 receptor is mainly expressed on peripheral immune cells and by microglia in the brain 
(Munro, Thomas and Abu-Shaar, 1993; Atwood and Mackie, 2010). Yet, CB2 receptor has 
been reported to be expressed also on neurons in some parts of the brain, particularly in the 
brain stem and the CA2 region of the hippocampus (Ashton et al., 2006; Suárez et al., 2009; 
García-Gutiérrez et al., 2010). Possible non-CB1 or non- CB2 cannabinoid receptors such as 
the  transient receptor potential vanilloid type 1 (TRPV-1),  the G-protein coupled receptor 
GPR55 and the GPR18 have been introduced , with GPR18 regarded to be a much likely 
candidate as a bona fide cannabinoid receptor (De Petrocellis and Di Marzo, 2010; Di Marzo 
and De Petrocellis, 2010, 2012; McHugh et al., 2012; Köfalvi, 2016). 
2-arachidonoylglycerol [2-AG] and Anandamide [AEA] are the two most-studied 
endocannabinoids and thus best-characterized ligands of the cannabinoid receptors. While 2-
AG has a relatively high affinity for both CB1 and CB2 receptors, AEA has a  higher affinity 
for CB1 but lower affinity for CB2 receptor (Felder et al., 1993; Mackie, Devane and Hille, 
1993; Atwood and Mackie, 2010). The efficacy of AEA at both CB1 and CB2 receptors and so 
with the strength of signal transduction is weaker compared to what is achieved with 2-AG 
which is a full agonist of both receptors. Hence AEA is a partial agonist of the cannabinoid 
receptors. 
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Figure 2.3B: Structural formula of the major endocannabinoids (adapted from Kano et al. 2009) 
In addition, there is a higher production of 2-AG in the CNS as compared to AEA (Murataeva, 
Straiker and MacKie, 2014). There are four known distinct pathways associated with the 
biosynthesis of anandamide and the main degradation enzyme being the fatty acid amide 
hydrolase (FAAH) (Di Marzo, Bifulco and De Petrocellis, 2004). Although the synthesis of 2-
AG occurs through a few known pathways, the best-studied pathway for 2-AG synthesis begins 
with the phospholipase-Cβ mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate, 
resulting in an intermediate product termed diacylglycerol (DAG). This intermediate product is 
then further cleaved by either diacylglycerol lipase α (DAGLα) or diacylglycerol lipase β 
(DAGLβ) to the end product    2-arachidonoylglycerol (2-AG) (Murataeva, Straiker and 
MacKie, 2014; Köfalvi, 2016). Nevertheless, 2-AG can also be synthesized by 
dephosphorylation of arachidonoyl-LPA or through a chronological action of PLA1 and lyso 
phospholipase C (lyso-PLC) (Nakane et al., 2002; Murataeva, Straiker and MacKie, 2014). 
B 
Introduction 12 
 
Figure 2.3C: Depiction of the Synthesis and degradation pathways of endocannabinoids (adapted 
from Di Marzo et al. 2004) 
 
Most of the 2-AG produced in the CNS can be traced back to the activity of DAGLα, while 
DAGLβ is more active in some peripheral organs like the liver (Bisogno et al., 2003). Both 
DAGL isoforms are highly conserved between species with mouse and human sharing a 
DAGLα homology of about 97 % while DAGLβ homology shared is at about 79 % (Murataeva, 
Straiker and MacKie, 2014). The degradation of 2-AG is based largely on the activity of 
monoacylglycerol lipase (MAGL) but other enzymes like serine hydrolase α-β-hydrolase 
domain 6 (ABHD6), serine hydrolase α-β-hydrolase domain (ABHD12) and fatty acid amide 
hydrolase (FAAH) also degrade 2-AG (Blankman, Simon and Cravatt, 2007; Kano et al., 2009). 
The metabolic products of 2-AG through the aforementioned pathways are mainly arachidonic 
acid and glycerol (Gellman et al., 2002; Freund, Katona and Piomelli, 2003). Several other 
degradation pathways for 2-AG are known that do not lead to arachidonic acid and glycerol as 
end products. COX-2 can oxidize 2-AG to produce prostaglandin glycerol esters, acyl glycerol 
C 
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kinase phosphorylation of 2-AG yields lysophosphatidic acid (LPA) and lipoxygenases oxidize 
2-AG to hydroperoxy derivatives. These metabolic products of 2-AG may activate other 
signalling pathways other than the endocannabinoid pathway, leading to excitatory instead of 
inhibitory effects. Hence alteration in 2-AG levels may not only affect the endocannabinoid 
system signalling but also the other signalling pathways mention above (Murataeva, Straiker 
and MacKie, 2014). 
2.4 The endocannabinoid system in brain ageing 
 
It is now widely accepted that disrupted intercellular communication is a major candidate-
hallmark of ageing (Lopez-Otin et al., 2013) and the profound role of the endocannabinoid 
system in the regulation of cell-cell interactions including neuron-neuron as well as neuron-glia 
communications cannot be overstated. In line with this, it could be expected that a reduced 
endocannabinoid activity would result in an accelerated progression of ageing. Similarly, 
impaired endocannabinoid system signalling has been reported to promote age-related and 
neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s diseases to 
name but a few (Bisogno and Di Marzo, 2010; Bilkei-Gorzo, 2012). Interestingly, literature 
reports and findings in our lab have it, that CB1 receptor deficient mice exhibit age-related 
changes in learning and memory abilities. While learning and memory performance 
deteriorated in old CB1 receptor knockout mice in various learning and memory tests , these 
were rather  significantly better in young CB1 receptor knockout mice compared to age-
matched littermates (Reibaud et al., 1999; Bilkei-Gorzo et al., 2005). Concomitantly, loss of 
principal neurons, altered glial activation and increased level of pro-inflammatory cytokines 
were recorded in old CB1 receptor knockout mice. These observed early age-related changes 
were confined to the hippocampus and influenced cognitive functions but not motor or sensory 
abilities (Bilkei-Gorzo et al., 2012). Consequently, it is most likely that CB1 receptor on 
GABAergic neurons influence the regulation of glial activity, thereby maintaining glial 
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homeostasis and providing a shield against early onset of age-associated dysfunctions (Bilkei-
Gorzo et al., 2005, 2012; Albayram et al., 2011).  Although CB2 receptor expression is higher 
in glial cells like microglia as compared to neurons (Stella, 2009) and the upregulation of the 
CB2 receptor has been linked to beneficial effects such as the restoration of tissue homeostasis 
during pathological neuroinflammatory conditions (Miller and Devi, 2011), deletion of CB2 
receptors did not result in detrimental effects such as  enhanced glial reactivity. Thus, it can be 
assumed that this receptor may not be responsible for the observed age-related changes. 
Nonetheless, it is not absolutely clear which of the endocannabinoids is more influential in the 
CB1 receptors mediated protection against early ageing. Owing to literature knowledge that 
endocannabinoids levels are reduced in ageing (Wang et al., 2003; Maccarrone et al., 2015), it 
is reasonable to think that an increased CB1 receptor signalling due to increased 2-AG or 
anandamide may delay ageing. Indeed, an increase in the activity of the cannabinoid system 
through anandamide elevation (Ortega-Gutiérrez, Molina-Holgado and Guaza, 2005; Tham et 
al., 2007) has been shown to promote anti-inflammatory response in vitro. Moreover, 
anandamide levels were described to be reduced in age-associated diseases such as Alzheimer’s 
disease, reporting a significantly low levels of this endocannabinoid in mid-frontal and temporal 
cortices in post-mortem samples (Jung et al., 2012). Furthermore, 2-AG mediated cannabinoid 
signalling has been shown to be bias for microglial M2 polarization, leading to overall reduction 
in inflammation  (Mecha et al., 2015) . Similarly, several reports have demonstrated a beneficial 
effect of cannabinoids during ageing, reporting that the effects of cannabinoids on cognitive 
functions were age-dependent. Young individuals were more vulnerable to cannabinoid 
agonists as older individual (Trezza, Cuomo and Vanderschuren, 2008).   A recent publication 
in our lab even went further to show that a chronic low dose of THC even improved cognitive 
ability in aged mice. Consequentially, exploration of the endocannabinoid system may open 
avenues for treatment of age-related pathologies including neurodegenerative diseases (Bilkei-
Gorzo et al., 2017). 
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2.5 Neuron-glial communication and the endocannabinoid system 
 
The importance of bidirectional communications between neurons and neighbouring glial cells 
for healthy functioning of the CNS is a widely accepted knowledge. In order to maintain a 
healthy microenvironment in the CNS, neurons, microglia and astrocytes have been reported to 
regulate each other by indirect interaction through soluble mediators and by direct interaction 
through membrane-bound mediators (Perry and Holmes, 2014). Microglial expression of the 
two main cannabinoid receptors has been reported. However, it is still a subject of debate 
whether these receptors are expressed only after activation of microglia or if they are 
significantly upregulated following microglia activation. Either way, microglia express 
cannabinoid receptors and can, therefore, be regulated by the endocannabinoid system (Stella, 
2009). There are a number of signalling pathways that may indirectly modulate immune 
functions in the CNS. Several neurotropic factors have been shown to modulate microglial 
reactivity. The brain-derived neurotrophic factor (BDNF) downregulates microglial expression 
of co-stimulatory molecule B7 and CD40 thereby modulating T cell recruitment and activation 
(Wei and Jonakait, 1999). Similarly, nerve growth factor (NGF) inhibits microglial expression 
of MHC class II (Neumann et al., 1998). Now, microglial activity can also be modulated by 
neurons through an array of GABA receptors expressed on microglia. GABA A and GABA B 
receptors expressed on microglia upon activation decrease pro-inflammatory cytokine release 
(Stella, 2009; Lee, Schwab and Mcgeer, 2011). In addition, GABAergic neurons have been 
shown to play an important role in the cannabinoid system associated modulation of microglial 
reactivity in the ageing brain. Mice constitutively deficient for CB1 receptors show symptoms 
of accelerated ageing characterized by increased glial activity, increased cytokines levels and 
an accelerated neuronal cell loss with progressing ageing. Interestingly, specific deletion of 
CB1 receptors on GABAergic neurons sufficed to elicit similar conditions (Bilkei-Gorzo et al., 
2005; Albayram et al., 2011; Albayram, Bilkei-Gorzo and Zimmer, 2012). However, similar 
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conclusions could not be reached in experiments with mice specifically deficient for CB1 
receptors on glutamatergic neurons. In line with this, the important role of GABAergic neurons 
in microglia regulation in the ageing brain cannot be overstated (Albayram et al., 2011; 
Piyanova et al., 2013). Nevertheless, of equal importance is the neuron-glial cell-cell 
modulation. Direct communication membrane-bound proteins play a crucial role in the 
crosstalk between neurons and microglia. The CD200 ligand on neurons and its corresponding 
CD200 receptor on microglia are such membrane-bound proteins. The interaction between 
neuronal CD200  and microglial CD200R  has been shown to maintain microglia in a quiescent 
state, preventing them from becoming overreactive (Hoek, 2000; Neumann, 2001; Jurgens and 
Johnson, 2012).  Another membrane-bound communication protein between neurons and 
microglia is the fractalkine (CX3CL1) on neurons and the corresponding receptor CX3CR1 on 
microglia. Their interaction has been reported to promote microglial survival and the initiation 
of pathological pain (Milligan, Sloane and Watkins, 2008; Rowinska et al., 2017). The receptors 
of these two neuroimmune regulator protein pairs (CD200R and CX3CR1) that are always 
situated on the microglia are transmembrane proteins coupled to immunoreceptor tyrosine-
based inhibitory (ITIM) motifs. ITIM acts via SHP-1 and SHP-2 phosphatases to inhibit or 
reduce microglia activation thereby modulating microglia reactivity (Billadeau and Leibson, 
2002). CX3CR1 activity has been reported to be crucial in hippocampal neurogenesis. Deletion 
or pharmacological blockade of CX3CR1 resulted in reduction or complete attenuation of 
hippocampal neurogenesis with reduced cognitive ability as the consequence. Furthermore, 
CX3CR1 expression levels have been shown to decrease during ageing and administering 
exogenous CX3CL1 to ageing animals led to improvement of hippocampal neurogenesis 
(Bachstetter et al., 2012; Justin et al., 2012; Sheridan and Murphy, 2013). Moreover, deficient 
CD200-CD200R signalling has been linked to microglia over-reactivation, leading to 
dopaminergic neurodegeneration (Zhang et al., 2011) and increasing ageing-associated 
properties. 
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2.6 Aim of this study  
 
The first aim of this study was to clarify how cannabinoid system activity influences brain 
ageing. Since we hypothesized that decreased microglial 2-AG production leads to early 
onset of cognitive deficits and age-related histological changes in the brain, we compared 
the declarative learning ability of the conditional DAGLα knockout mice and wild-type 
littermates in a longitudinal study. We further characterized the spatial learning and working 
memory abilities of these animals. Secondly, we hypothesized that reduced cannabinoid 
signalling between microglia and the regulatory hippocampal GABAergic neurons leads to 
upregulation of microglial activity thereby promoting neuroinflammatory changes in the 
ageing brain. In order to test this hypothesis, we assessed microglial reactivity using 
organotypic hippocampal slice culture from GABA-specific CB1 knockout (GABA-Cnr1-/-
) and microglia-specific DAGLα knockout (Dagla-/-) animals. Then we went further to 
compare the reactivity of microglia in vivo to LPS in the hippocampus of wild-type and 
GABA-Cnr1-/- mice in different age groups. We also hypothesized that increased 
cannabinoid signalling due to increased anandamide levels influences microglial reactivity. 
Thus, we assessed microglial reactivity in different age groups of FAAH knockout animals 
and wild-type littermates. Lastly, we hypothesized that disturbed endocannabinoid 
signalling leads to an early onset and/or exacerbated senescence-associated phenotype in 
microglia. Hence, we compared lipofuscin accumulation, expression of some GABA 
receptors and cytokines in isolated microglial cells of  Dagla-/-  and GABA-Cnr1-/- animals 
alongside their wild-type littermates in different age groups. This was followed by 
characterization of age-related histological changes of neuron-glial communication markers 
in Dagla-/- animals in different age groups
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3. Materials and Methods 
 
If not stated otherwise, all applied chemicals were acquired from Sigma-Aldrich, Invitrogen, 
Roche, Fluka, Applichem, Merck, Applied Biosystems and Carl Roth. Contact information are 
provided in the appendix. 
3.1 Equipment 
 
Analytical balance   BP 121 S, Sartorius 
BD FACSCantoTMII Flow Cytometer BD Biosciences 
Bioanalyzer    Agilent 2100 bioanalyzer, Agilent  
CCD camera   AxioCamMRm, Zeiss  
   KY-F75U, JVC 
Cell culture incubator                                Binder GmbH 
Centrifuges   Biofuge fresco, Heraeus Instruments 
   Biofugepico, Heraeus Instruments 
Cryostate   CM 3050 S, Leica 
Hamilton micro syringes   Sigma-Aldrich 
Homogeniser   Precellys® 24, Bertin Technologies 
Laminar flow hood   Herasafe, Kendro 
Vibratome   VT1200 S Microtome,Leica 
Magnetic stirrer   MR 3001 K, Heidolph, Fisher 
Microplateanalyzer   MRX TC II, Dynex Technologies 
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Microscope   Axiovert 200 M, Zeiss 
Millicell insert   BD Falcon, USA 
PCR iCycler   iCycler, Bio-Rad Laboratories 
pH meter   inoLab, WTW 
Real-Time Cycler   7500 Real-Time PCR Detection System, 
   Applied Biosystems 
Spectrophotometer   NanoDrop ND-1000, Thermo scientific 
Stereotaxic instrument   Stoelting, USA 
Surgical thread   Ethicon Endo-Surgery Europe GmbH 
Vortexer   Vortex-Genie 2, Scientific Industries 
Ultrasonic bath   Ultrasonic cleaning bath USC-THD, VWR 
3.2 Software  
 
AxioVision LE     Carl Zeiss, Germany 
EthoVision®       NoldusVersion XT 8.15 
ImageJ       Wayne Rasband, USA Version   1.47v  
Mouse-E-Motion      Infra-E-Motion, Germany 
Microsoft Office 2016     Microsoft, Germany 
Prism     GraphPad Software, Inc. Version 5.03c 
Statistika     StatSoft, Inc. Version 6 (2001) 
VideoMot      TSE Systems, Germany 
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3.3 Chemicals and reagents 
 
 
3.3.1 Chemicals 
 
Albumin bovine Fraction V, pH 7.0 standard   Serva grade, lyophil. (BSA)  
Brilliant Blue R-250      Sigma-Aldrich 
1-Bromo-3-chlorpropane (BCP)    Sigma-Aldrich 
BrdU (B5002-250mg)     Sigma-Aldrich 
Cremophor® EL/ Kolliphor®EL    Sigma-Aldrich 
DAPI Fluoromount-G®     SouthernBiotech 
D(+)-Glukose       Sigma-Aldrich 
Ethidium bromide solution (10 mg/ml)    Sigma-Aldrich 
Fluoromount-G®      SouthernBiotech 
H2O2         Sigma-Aldrich 
2-Methylbutan/ Isopentan     Sigma-Aldrich 
KCl        Sigma-Aldrich 
MgCl2 Hexahydrate      Applichem 
NaCl        Roth 
NaOH        Millipore 
Paraformaldehyd      Sigma-Aldrich 
PBS tablets       Gibco life technologies 
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Percoll       GE Healthcare, Germany 
Rnase free water     Gibco life technologies 
SDS ultra pure     Roth 
TRIzol® Reagent     Thermo Fisher 
TRIS       Roth 
TRIS-HCL      Roth 
Triton-X 100      Sigma-Aldrich 
Tween-20      Sigma-Aldrich 
β-mercaptoethanol     Sigma-Aldrich 
3.3.2 Kits 
 
GoTaq® Green Master Mix     Promega 
BCA Protein Assay Kit    Thermo Fisher (PierceTM) 
Mouse TNF-α ELISA     eBioscience (88-7324) 
Mouse IL-6 ELISA     eBioscience (88-7064) 
Mouse IL-1β ELISA     eBioscience (88-7013) 
 
3.3.3 Buffers and Solutions 
 
All buffers and solutions were prepared with dH2O, whereas all chemicals were purchased from 
Applichem, Life Technologies, Merck, Carl Roth or Sigma-Aldrich except the contrary is 
stated. 
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ELISA Coating buffer  
10x coating solution       1.1ml  
MilliQ water        9.9ml  
capture Ab (1:250)       44 μl  
ELISA Wash buffer  
PBS         1l 
Tween-20       500µl 
ELISA Assay diluent  
5x assay diluent       8ml  
MilliQ water        32ml  
ELISA Detection Ab solution  
assay diluent        11ml  
detection Ab        44 μl  
ELISA Avidin-HRP solution  
assay diluent        11ml  
Avidin-HRP        44 μl  
ELISA Stop solution  
1M H3PO4 or 2N H2SO4  
4% PFA pH = 6.9  
1 x PBS        800ml  
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PFA power         40g  
Adjust to 1l with 1xPBS 
3.3.4 Antibodies 
 
Primary Antibodies 
Anti-Iba1 (019-19741, rabbit)    Abcam 
Anti-Iba1 (016-20001, rabbit)    Wako 
Anti-CD200/OX2 (ab33734, rat)    Abcam 
Anti-CD200R/OX102 (ab34097, mouse)   Abcam 
Anti-CX3CL1 (ab25088, rabbit)    Abcam 
Anti-CX3CR1 (c8354, rabbit)     Sigma-Aldrich 
Secondary Antibodies 
Alexa Fluor® 488 goat anti-rabbit    Invitrogen, A11008 
Alexa Fluor® 488 goat anti-mouse    Invitrogen, A11007 
Alexa Fluor® 594 goat anti-rabbit     Invitrogen, A21207 
Alexa Fluor® 594 goat anti-rat    Invitrogen, A11001 
Alexa Fluor® 647 donkey anti-rabbit    Invitrogen, A3157 
Cy3 goat anti-rabbit    Invitrogen, A10520 
3.3.5 Enzymes 
 
Proteinase K       NEB 
Superscript II Reverse Transcriptase    Invitrogen 
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Taq Polymerase      NEB 
Phusion High Fidelity DNA Polymerase   NEB 
3.4 Media and solutions 
 
 
3.4.1 OHSCs media 
 
Dissection medium for OHSCs 
MEM medium (Gibco)      500ml 
200mM Glutamine (Gibco or Sigma)    5ml 
HEPES        5ml 
 
OHSCs medium  
MEM (Gibco)       100ml  
HBSS (Gibco)       50ml  
Heat inactivated horse serum (GE Healthcare)   50ml  
Glutamine (Gibcoand Sigma)     2ml  
Glucose        2ml  
Amphotericin B (Sigma)      3ml  
Pen/Strep 100x (Gibco)      2ml 
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3.4.2 ACSF solution 
 
ACSF solution A without Ca/Mg 
NaCl        8.66g 
KCl        0.224g 
Fill up to 500ml with MilliQ water 
ACSF solution A with 1.1mM Ca2+ 
NaCl        8.66g 
KCl        0.224g 
CaCl2 x 2 H2O      0.162g 
MgCl2 x 6 H2O      0.163g 
Fill up to 500ml with MilliQ water 
ACSF solution B 
Na2HPO4 x 7 H2O      0.214g 
NaH2PO4 x H2O      0.027g 
Fill up to 500ml with MilliQ water 
Mix A and B 1:1 for use 
 
3.4.3 Microglia isolation solution / FACS solution 
 
Isolation medium 
DMEM with 4.5g/l glucose     450ml 
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FCS        50ml 
Collagenase solution from 10 mg/ml stock 
Collagenase       500µl 
Medium       5ml 
 Dispase solution from 10 mg/ml stock 
Dispase       500µl 
Medium       5ml 
 
Inactivation solution (20% FCS) 
Heat inactivated FCS      20ml 
1 x HBSS       80ml 
Percoll 30% 
Percoll        30ml 
PBS        120ml 
Percoll 70% 
Percoll        120ml 
Medium       30ml 
FACS buffer 
Heat inactivated FCS      1ml 
PBS        50ml 
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Blocking solution 
CD16/32       1µl 
FACS buffer       300µl 
Fluorescent labelled antibodies mix 
CD11b-APC diluted 1:200 in FACS solution 
CD45-e450 diluted 1:200 in FACS solution 
3.5 Animals 
 
Animals used in this study were, on the one hand, mice with GABAergic neuron specific 
deletion of cannabinoid receptor 1 (GABA-Cnr1-/-), and on the other hand, mice with microglia-
specific deletion of Dagla (LysM-Dagla-/-) and inducible microglia-specific deletion of Dagla 
(Tam-CX3CR1-Cre-Dagla-/-) together with their wild-type littermates. A constitutive FAAH 
deficient mouse line was also used. Mice were generated on a congenic C57BL/6J background, 
housed sex-isolated in groups of 2 to 5 mice, allowed access to water and food ad libitum and 
kept in a reversed light-dark cycle (lights on :19:00; lights off: 9:00) in the House of 
Experimental Therapy, University of Bonn. Housing conditions were stable at about 21°C and 
55 % relative humidity. The experiments were performed with conditional mice and their 
corresponding littermates aged 2, 12 and 18 months. For the Organotypic Hippocampal Slice 
Cultures, 3 to 5 days old pups were used. The experiments and treatment of animals were carried 
out as stipulated by the guidelines of the European Union Council Directives 86/609/EEC and 
were approved by the Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-
Westfalen. 
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3.6 Behavioural experiments and animal treatment 
 
3.6.1 Subcutaneous injection of Tamoxifen for Cre induction in Tam-CX3CR1-Cre-
Dagla-/-  mice 
 
Approximately four weeks old mice were subcutaneously injected on day 0 and day 2. Mice 
were administered a total of 200 µl of 20 mg/ml Tamoxifen (Sigma) in corn oil (Sigma) on day 
0. The injection was given in 50 µl volume at the flanks and shoulders of an anaesthetized 
mouse. The injection was repeated on day 2. A recombination of about 90 % is expected in 
three to four weeks.  
3.6.2 Morris water maze (MWM) 
 
In a longitudinal test of cognition, the spatial learning and memory ability of Tam-CX3CR1-
Cre-Dagla-/-  female mice was tested in the MWM task (Barnes, Suster et al. 1997). A circular 
pool (1.2 m in diameter and 0.6 m in height) made of white PVC was used. First, the tank was 
filled with water to a depth of about 30 cm maintaining a temperature of about 24 °C. Then a 
non-toxic white paint was employed to make the water opaque so as to veil the rescue platform. 
The rescue platform was 15 cm high and 8 cm in diameter painted white to camouflage with 
the opaque water. Now, the platform was placed inside the tank approximately 1.5 cm under 
the water level, serving as an escape platform. The pool was located in a closed sound proof 
room with numerous extra-maze visual cues. Plastic placards of various shapes and colours 
were attached to the wall of the tank and act as additional cues. A camera fixed on the ceiling 
above the pool was used to record video signal that was simultaneously transmitted to a 
computer. With the aid of an automatic tracking system installed on the computer, the swim 
paths are captured and escape latencies, total path length and swim speed are calculated.  
In the acquisition phase, which is the first phase of the Morris water-maze test, the learning 
ability of the mice was compared in the test groups. The platform was positioned at a fixed spot 
in the pool during the entire acquisition period. The animals were tested for six days consisting 
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of four consecutive sessions per day. There are four points along the wall of the pool designated 
as North, South, East and West (N, S, E, W) that divide the pool into four equal quadrants and 
also serving as starting points. The mice were always released facing the wall of the circular 
pool during the entire trials. In the first two days, all four sessions were started from the same 
point (W).  However, from the third day onwards, the animals were released from all starting 
points (W, N, E, W) during sessions. The goal is for the mouse to reach the rescue/escape 
platform and stay on it for a period of 5s in which case the experiment ends automatically. Mice 
were allowed to remain on the platform for 30 s before placing them back into their respective 
home cages. Should the mouse fail to locate the platform within 70 s, the mouse was guided 
gently with the hand to the platform and in this case,  the trial was recorded as an escape failure 
with an arbitrary latency of 70 s.  In the second phase, referred to as the probe trial on day 7, 
the memory strength is tested. For this purpose, the rescue platform is removed and the mice 
are allowed to swim for 70 s. The more time spent in the quadrant where the platform was 
placed indicates better memory strength. The third and last phase is the reverse phase. Here we 
test the flexibility of the spatial memory. On day 8 to 10, the rescue platform is placed back 
into the pool, but this time on the opposite side to where it was placed during the acquisition 
phase. Mice were tested when they were 2 and 12 months old. The experiments were performed 
during the hours of 10:00 a.m. and 14:00 a.m., which is the active phase of the animals. 
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Figure 3.5.2: Depiction of a Morris Water Maze experimental set-up. During the acquisition and reverse 
phases, the platform is placed to the north and south, respectively. While the platform is removed during 
the probe trial (modified from Albayram et al, 2012) 
 
3.6.3 Partner recognition test 
 
In another longitudinal test, a social preference test was carried out with Tam-CX3CR1-Cre-
Dagla-/-   male mice when they were 2 and 12 months old. The trials were carried out in an open-
field arena (44 cm x 44 cm) in a dimly illuminated and sound isolated environment. In order to 
exclude possible environment associated interference and result falsification (Haller, 2002; 
Thiemann, 2009), the test animals are habituated to the arena for five minutes daily on three 
consecutive days. Meanwhile, the sawdust, covering the floor of the arena remained unchanged, 
leading to saturation with mice odour. The trials, consisting of two sessions, started by putting 
male animals of the same age with test animals into grid cages. Now, a mouse in a grid cage 
was placed in a corner 12 cm away from the walls. This is labelled as     “ remain”. On the 
opposite side to the remain cage, an object with similar size (in this case a Pepsi can) was placed. 
With the aid of the EthoVision XT software (Noldus, Information Technology Inc.), the 
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location of the test mice was recorded for 9 minutes. In the second session, the Pepsi can object 
was removed and replaced with a grid cage (termed New) containing a new mouse whilst the 
remain-cage was left untouched. After an interval of 30 minute (day one), 1 hour (day 2) and 2 
hours (day three), the test mouse was placed again in the arena and allowed to explore for 3 
minutes. Of interest, was the time the mice spend interacting (the nose of the mouse is not 
more than 1 cm from the wall of the grid cage) with the Pepsi can, remain and new mice. A 
sign for partner recognition is a significantly higher time spent investigating the new partner.  
3.6.4 Social preference test after icv LPS treatment (Sickness behaviour) 
 
In order to test the social preference of GABA-specific CB1 knockout mice (GABA-Cnr1-/-) 
after intracerebroventricular (ICV) injection of LPS, animals age 3, 12 and 18 months old were 
housed in single cages and kept in reverse dark/light cycle for a period of one week. On the 
treatment day, animals were administered intraperitoneally (i.p) 0.1 mg/kg buprenorphine thirty 
minutes before surgery. The animals were then anaesthetized with ketamine/xylazine (0.1 ml 
ketamine, 0.2 ml xylazine from an injection solution diluted to 2 ml with saline or connected to 
a mask that supplies air with a mixture of 75 % O2, 25 % N2 and 3-5 % of isoflurane after they 
were fixed to a stereotaxic instrument (Stoelting, USA). For an incessant and sustained 
anaesthetic effect, isoflurane was maintained at about 1.5-2 %. Now the scalp of the mouse was 
cut open with a scalpel, cleaned with a cotton swab and the skull treated with 3 % hydrogen 
peroxide to reveal the bregma and pattern of the skull. Employing the stereotaxic instrument, 
the skull was carefully punched above the right dorsal ventricle (coordinates:  -0.6; -1.2 from 
bregma) with a fine drilling machine. Now with the aid of a Hamilton micro syringe (Sigma-
Aldrich) , either 5 µl artificial cerebrospinal fluid (ACSF) or 100 ng LPS in 5 µl ACSF was 
injected into the punched hole (coordinates:  -0.6; -1.2; -2 from bregma). The area of surgery 
was disinfected and stitched close with surgical suture on needle holder. The animal was then 
put back into the cage and allowed to recover. Behavioural test only followed 24 hours after 
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surgery. The sickness behaviour was assessed after the recovery and resting period. Similar to 
previous experiments, the trials were carried out in an open-field arena (44 cm x 44 cm) in a 
dimly illuminated and sound isolated environment. A mouse in a grid cage (same sex to test 
animals) was placed in a corner 12 cm away from the walls and on the opposite side to the 
mouse in the grid cage, an empty grid cage was positioned. Using the EthoVision XT software, 
the test mouse interaction with either the empty cage or the cage containing a mouse was 
recorded for 6 min. At the end of the tests, the animals were anaesthetized with isoflurane, 
followed by transcardial perfusion with ice-cold PBS. The brains were harvested, cut into two 
halves longitudinally and one-half directly shock frozen in dry ice for RT- PCR. The other half 
was processed for immunohistochemical staining. Here the brain half was fixed in 4 % PFA for 
3 hours, cryoprotected in 20 % sucrose for 24 hours and lastly shock frozen in dry ice-cooled 
isopentane.  
 
3.7 Molecular biological methods 
 
3.7.1 Transcardial perfusion 
 
Mice were collected and anaesthetized with a mixture of ketamine/xylazine. Now, the chest 
was cut open, allowing a catheter with a 25G needle to be inserted into the left ventricle. The 
right atrium was then cut open. The perfusion was then performed with cold phosphate-buffered 
saline (PBS) at a flow rate of 4 ml/min to wash out the blood, then at the same flow rate, 4 % 
paraformaldehyde (PFA) in PBS was used to fix the brain. A post fixation step followed, where 
the isolated brains were kept in a 4 % PFA solution for 24h at 4 oC. Lastly, the brains were 
transferred into a 20 % sucrose solution for another 24 h for cryoprotection before finally snap 
frozen in ice cooled isopentane for storage at -80°C.  
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3.7.2 Microglia isolation and FACS analysis of lipofuscin 
 
The deletion of CB1 receptors may lead to an early onset of age-related phenotypes in the brain 
with microglia cells readily showing senescent phenotype in the brain of GABA/Cnr1-/- mice 
as compared to their age-matched wild-type siblings. Here the amount of lipofuscin contained 
in the microglia is an indicator of the ageing process of these cells. For this purpose, we isolated 
microglia (precisely intracerebral lymphocytes), stained for microglia and proportion of 
lipofuscin accessed by FACS. Microglia isolation starts with transcardial perfusion and brain 
harvesting. Now a brain was homogenized in 1 ml of medium by chopping with a scalpel in a 
35 mm dish, then 3 ml medium was added. An enzymatic solution ( Collagenase and Dispase)  
was added and placed in the incubator (37°C, 5 % CO2 under stirring every 10 minutes). After 
45 minutes, a DNase I solution was added for another 45 minutes.  A 20 % fetal calf serum 
(FCS)  in 1 x HBSS was used to stop the enzymatic reaction. The homogenate was collected in 
50 ml falcon tube and centrifuged for 10 minutes at 4°C and 300 g. The pellet was resuspended 
in 1 ml medium and 4 ml medium was added. Using a 20G needle and a 20 ml syringe, the 
pellet was further dissociated to single cells. The homogenate was filtered through a 100 µm 
filter and 10 ml medium was used to wash the filter down. Again, a centrifugation step at 4°C 
and 300 g for 10 minutes was performed. 
A discontinuous gradient density centrifugation step using Percoll was then performed. First 
the pellet was resuspended in 1 ml 70 % Percoll and then 14 ml Percoll was added. Now 15 ml 
of 30 % Percoll was gently added to the tube, taking care that the phases are not mixed together. 
On top of the 30 % Percoll phase, 15 ml 1 x PBS was added and centrifuged for 25 minutes at 
room temperature and 600 g without brakes. Thereafter, the material (myelin and debris) at the 
interphase between 30 % Percoll and 1 x PBS was carefully discarded. We now collected the 
interphase ring between the 70 % and 30 % phases (intracerebral lymphocytes) into a new 50 
ml falcon tube and filled up to 45 ml with medium. Another centrifugation step at 4°C and 400 
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g was performed for 10 minutes. The pellet was resuspended in 1 ml FACS buffer in a 1.5 ml 
Eppendorf tube and centrifuged at 4°C and 1700 g  for 5 minutes. Next, for the FACS analysis 
of lipofuscin levels, the isolated cells were stained for microglial markers (CD11b and CD45). 
While CD11b primary antibody was coupled with APC a far red dye, the CD45 primary 
antibody was coupled to a blue dye, e450. Lipofuscin displays it autofluorescence property at 
a wavelength range of 480-550.  The isolated cells were incubated in CD16/32 blocking 
solution for 15 minutes to block the Fc- receptor binding sites on the cell surface. Afterward, 1 
ml FACS-buffer was added and cells were centrifuged for 5 minutes at 1700 g rpm. The pellet 
was incubated in an antibody-mix of both CD11b-APC and CD45-e450. For control and FACS 
settings some samples were stained only with CD11b-APC, CD45-e450 and a negative control, 
where no antibody was added at all. The samples were incubated for 15 minutes after which 1 
ml of FACS buffer was added to samples and centrifuged for 5 minutes at 1700 g rpm. The 
pellets were now resuspended in 200 ml FACS buffer and analysed by FACS. For each sample, 
we analysed 100-150 microglial cells by comparing the lipofuscin-like autofluorescence within 
the microglia.  
3.7.3 Organotypic hippocampal slice culture 
 
To investigate the interchanging role of the endocannabinoid system on microglia- neuron 
interaction, organotypic hippocampal slice culture experiments with GABA-Cnr1-/- mice (CB1 
specifically knocked out in GABA neurons) and LysM-Dagla-/- mice (Dagla specifically 
knocked out in microglia) were performed. A laminar flow hood was cleaned and 6-well plates 
containing 1 ml of culture medium pre-warmed in the incubator were prepared. Thereafter, all 
instruments to be used were sterilised in 70 % ethanol. The instruments were, however, rinsed 
in dissection medium before use. Now, three to five days old pups were collected and sacrificed 
by decapitation and the head placed in a 10 cm petri dish, followed by sterilisation of the head 
with 70 % ethanol. Next, the head was dissected and the brain placed on ice in a petri dish with 
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wet filter paper, minding not to touch the brain with unsterilized instruments. Subsequently, the 
cerebellum was removed with a scalpel and two brains were fixed (dorsal side down) to the 
vibratome plate stabilised by agarose blocks. Then, the vibratome chamber was filled with cold 
dissection medium, while placing crunched ice blocks around the chamber. After this, the brains 
were cut into 350 µm slices, collecting the slices containing the hippocampus with a Pasteur 
pipette into a new petri dish containing dissection medium. Now, with the aid of a microscope, 
slices containing clearly hippocampal structure (dentate gyrus, CA1 and CA3) and entorhinal 
cortex were isolated without lesion to structure. Consequently, four to six slices were collected 
per brain with a Pasteur pipette and transferred into a petri dish filled with culture medium on 
ice. Now, the slices were picked with little culture medium alongside into a Millicell insert and 
excessive medium was removed with a pipette. Finally, the insert was placed into the prepared 
6-well plate with forceps and placed back into the incubator (35°C and 5 % CO2). Medium was 
changed a day after preparation but subsequently every two to three days. Slices were kept in 
culture for two weeks before starting experiments. For the experiment, we activated the 
microglia in the slices by stimulating with 5 µg/ml LPS for three consecutive days. Each day, 
the medium was collected in Eppendorf tubes, shock-frozen in liquid nitrogen and replaced 
with fresh medium before the next LPS stimulation. Collected samples were stored in -80°C 
pending further experiments. Four conditions were investigated; wild-type, wild-type 
(stimulated), Knockout and knockout (stimulated). Thereafter, glial activity was assessed as 
time-dependent increase in TNF, IL-1β and IL-6 in the media using ELISA. 
3.7.4 LPS injection 
 
As a further approach, we evaluated the effect of CB1 receptor deletion from GABAergic 
neurons on microglial activity in situ. Here, 2 months old knockout and wild-type mice were 
intraperitoneally injected with 0.8 mg/kg LPS or saline, once for the single injection paradigm 
or 4 times on four consecutive days for the multiple injection paradigm. Mice were sacrificed 
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24 hours after the last injection and microglial activity was assessed. Change in microglial 
number in the hippocampus and expression of cytokines were determined. 
3.7.5 Enzyme-linked immunosorbent assays (ELISA) 
 
Employing the Read-Set-Go ELISA Kit, TNFα, IL-1β and IL-6 levels in the collected media 
samples were measured. ELISA is an antibody-mediated characterisation of protein in a given 
sample, whereby the levels of the proteins of interest is in direct correlation with the light-
sensitive signals that are detected by enzymatic oxidation of 3,3’, 5,5’-Tetramethylbenzidine 
(TMB). The experiment was performed as instructed by the manufacturer. For short, a 96-well 
plate was coated with coating solution and incubated for 24 hours at 4°C, washed several times 
with washing buffer and assay diluent applied for 1 h at room temperature for blocking, then 
washed again. OHSC media sample were used at a 1:10 dilution while assay standards were 
diluted according to manufacturer’s instructions. Now, 100 µl/well of standards and samples 
was used in duplicates. The measurements were done at a wavelength 450 nm, whereas the 
reference was at 570 nm. 
 
3.7.6 RNA isolation 
 
Total   RNA   from frozen half-brain tissue or isolated primary microglia was extracted using 
the   TRIzol® reagent   (Life Technologies).   For half-brain, tissue was transferred into 2 ml 
Precellys tubes with 1.4 mm ceramic beads (peqLab, Erlangen) containing 1 ml TRIzol®. The 
tubes were placed into the Precellys centrifuge and the tissues were homogenized in 2 cycles 
for 20 sec. The homogenization step was repeated again for optimum outcome. For isolated 
microglia, 500 l TRIzol® is added to the cells in 1.5 ml Eppendorf tubes and pipetted up and 
down several times. From this point on samples were handled similarly, irrespective of sample 
initial state.  Homogenized samples were centrifuged at 12000 g for 10 min at 4°C. The 
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supernatants were then transferred into fresh  1.5  ml Eppendorf tubes after which 200 µl 1-
bromo-3-chloropane (BCP) was added. Now, the samples were then continually vortexed for 
30 s and later incubated at RT for 5 min. This was followed by another centrifugation step at 
12000 g for 10 min at 4°C, leading to formation of phases. The upper phase, containing the 
RNA was transferred into a new tube and isopropanol was added at a ratio of 1:1 for 
precipitation of RNA. Again, the samples were vortexed for  30 s, but this time incubated for 
10 min at RT before centrifugation (12000 g, 10 min, 4°C).  The supernatant was discarded and 
the precipitated RNA washed three times in 1 ml 75 % ethanol. Subsequently, another 
centrifugation step was done at 12000 g for 5 min. The RNA pellet was dried for 30 min at 
47°C and dissolved in 50 µl RNase-free water and the concentration was determined by optical 
density measurement using the NanoDrop 1000. 
3.7.7 RT- cDNA synthesis 
 
In order to transcribe the isolated and purified RNA into cDNA, a reverse transcription 
polymerase chain reaction was performed, using the SuperScript®  II for RT-PCR (Life 
Technologies). First, RNA was prepared to contain an equal concentration at a maximum of 
1000 ng per sample in a total volume of 11 µl in DEPC. Then, 1 µl of 0.5 µg/µl Oligo-dt and 1 
µl of 100 mM dNTPs (Sigma-Aldrich) was added to each reaction before the thermo cycler was 
run under the cycler parameters indicated below: 
Cycling parameters   
65°C 5 min 
4°C 3 min 
 
Now, the master mix illustrated below was added to each sample. 
Master mix for a sample   
5 x first strand buffer (Life Technologies)      4 µl 
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DTT 0.1 M (Life Technologies)      2 µl 
 
Thereafter, the following program was applied: 
Cycling parameters   
42°C 2 min 
4°C 3 min 
 
At this point, we added 1 µl SuperScript®  II Reverse Transcriptase to each sample and the 
following program was run. 
Cycling parameters   
42°C 50 min 
70°C 15 min 
4°C 10 min 
 
The transcribed cDNA was diluted as required with RNase-free water and stored at -20°C 
pending usage. For the gene expression analysis, 4 µl of each sample containing 30 ng cDNA 
was used per well for the TaqMan reaction. 
3.7.8 Real time quantitative polymerase chain reaction (RT-qPCR) 
 
The expression levels of the cytokines of interest were determined using the TaqMan® Gene 
Expression Assay from Applied Biosystems, Darmstadt, Germany. Here, 4 µl of each sample 
containing 30 ng cDNA was added to 6 µl master mix: 
Master mix for a sample   
TaqMan®  master mix      5 µl 
20 x TaqMan®   Gene Expression primer (Table x)      0.5 µl 
RNase-free water      0.5 µl 
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Lastly, samples were placed in the LightCycler® 480 from Roche, Germany and ran, applying 
a defined set of parameters (95°C for 10 min; 45 cycles at 95°C for 15 s and 60°C for 1 min). 
GAPDH being used as the housekeeping gene, relative gene expression levels were calculated 
with the 2−ΔΔCT method (Livak & Schmittgen, 2001). 
TaqMan® Gene Expression  
Target genes Assay ID 
IL-1β Mm00434228_m1 
IL-6 Mm00446190_m1 
TNFα Mm00443258_m1 
GAPDH Mm99999915_g1 
 
3.7.9 Immunohistochemical staining 
 
The frozen brains or half-brains were serially cryosectioned into 16 µm coronal sections using 
a Cryostat (Leica CM3050 S; Leica Microsystems, Heidelberg, Germany). Sections were 
mounted onto glass slides and stored at -80°C, if not immediately processed. 
 
Iba1 Staining 
For Iba1 staining, sections were permeabilised with 0.5% Triton X-100 in PBS for 1 h at room 
temperature. After a short washing step, sections were blocked with 3% BSA in PBS and after 
washing, incubated with rabbit anti-Iba1 IgG (Wako, Japan) primary antibody diluted to 1:2000 
in 3% BSA in PBS and incubated for 48 h at 4 °C. Next, after washing, slides were blocked by 
dipping them into 3% BSA in PBS and incubated with a secondary antibody (AF488 conjugated 
donkey IgG anti-rabbit, Invitrogen, USA) in 1:1000 dilution in 3% BSA in PBS for 2 h at room 
temperature. Finally, the slides were briefly washed and covered with Vectashield Mounting 
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Medium containing 4′,6-diamidino-2-phenylindole  (DAPI)  (Vector Laboratories Inc., 
Burlingame, CA). 
CX3CR1:CX3CL1 and CD200R:CD200L staining 
The sections were dried after collection from the freezer on a hot plate for 30 min at 40°C, and 
then washed in PBS for 10 min at RT. Sections were incubated in 10 mM sodium citrate (pH 
8.5) for 30 min at 65°C. Now, sections were permeabilised in 0.5 % TritonX-100 in PBS for 20 
min, washed and then blocked in 10 % normal goat serum (NGS) and 3 % BSA in PBS for 1 h 
all at RT.  At this point, after washing, the various primary antibodies (Anti-CD200/OX2 
[ab33734, rat], Anti-CD200R/OX102 [ab34097, mouse], Anti-CX3CL1 [ab25088, rabbit], 
Anti-CX3CR1 [c8354, rabbit]) were added diluted 1:500 in 3 % BSA in PBS and incubated for 
24 h at 4°C. Afterwards, sections were washed 3 times in PBS and the respective secondary 
antibodies (Alexa Fluor® 488 goat anti-mouse, Alexa Fluor® 594 goat anti-rat, Cy3 goat anti-
rabbit) were added diluted in the same solution and same concentration as the primary 
antibodies before incubating for 1 h at RT. Another washing step in PBS and Milli-Q water 
followed. Lastly, slides were covered with Vectashield Mounting Medium containing 4′,6-
diamidino-2-phenylindole  (DAPI)  (Vector Laboratories Inc., Burlingame, CA). 
 
3.8 Image acquisition and analysis 
 
Fluorescence images were acquired using a Zeiss Axiovert 200 M fluorescent microscope (Carl 
Zeiss Microimaging, Germany) and the pictures were converted to 8-bit grey scale. For 
quantitative analysis, we determined microglia densities/sizes and in neuron-microglia 
communication markers (neuroimmune regulators) only the densities within the hippocampus 
using the Image J software (Image J 1.42q and 1.47v, NIH, USA). Neuroimmune regulators 
signal is given in average signal intensity of the areas covered in the hippocampus. Density of 
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microglia was given as number of Iba1 positive cells per mm2. For statistical analysis, four to 
six representative slides were evaluated from each animal. Groups were compared using two-
way ANOVA followed by Bonferroni test with post hoc test.  
3.9 Statistics 
 
In general, result data are presented as means ± SEM, whereby numbers of animals or samples 
are indicated in the respective figures. A Mann-Whitney U test, two-way ANOVA with 
Bonferroni´s post-hoc test or Students t-Test was used to assess data statistical significance, 
setting P-value at p < 0.05. GraphPad Prism 5.03 or Statistica software was used.
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4. Results 
 
4.1 GABA-CB1-/- leads to enhanced neuroinflammation in ageing 
 
Constitutive deletion of CB1 receptor has been shown to promote aging. This was accompanied 
by increased neuroinflammation as a result of changing microglia reactivity. Microglial cells in 
constitutive Cnr1-/- mice had increased levels of activation and aging markers (Albayram et al. 
2011). Here we asked whether a specific deletion of Cnr1-/- on GABA neurons may suffice to 
induce property-changes in microglia and the brain. 
4.1.1 Disturbed regulation of cytokine production in GABA-Cnr1-/- mice in OHSC 
system 
 
We hypothesized that the microglial reactivity is disturbed in the knockout model. Hence, we 
tested cytokines production regulation in organotypic hippocampal slice cultures that were 
obtained, prepared and maintained as detailed in materials and methods. ELISA was then 
performed as instructed by the manufacturer to measure cytokines levels. 
Figure 4.1.1: Representative microphotograph of organotypic hippocampal slices in culture.The 
length of the scale bars is 200 μm 
 
 
One-way ANOVA revealed a highly significant LPS treatment effect in IL1β (F(3, 30) = 30.55, p < 
0.001),  IL-6  (F(3, 20) = 54.49, p < 0.001) and TNFα (F(3, 20) = 11.48, p > 0.01) after 24h 
stimulation. Post hoc analysis of the data also showed that IL1β and IL-6 production was 
Day 0 Day 1 Day 7 Day 14 
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significantly higher in the stimulated similarly in both genotypes (p < 0.001). TNFα production 
was significantly higher in the stimulated groups in the WT (p < 0.01) and in the GABA-Cnr-/-  
samples (p < 0.05). There was a significant increase in TNFα production in the unstimulated 
GABA-Cnr-/- samples compared to unstimulated WT control (p < 0.01). Figure 4.1.1A.  
 
Figure4.1.1A: ELISA measurement of OHSC supernatants for cytokine release after 24h LPS 
stimulation. Stimulation with LPS for 24h led to increased production of IL1β, IL-6 and TNFα 
irrespective of genotype. TNFα level was higher in unstimulated GABA-Cnr1-/- compared to 
unstimulated WT. One-way ANOVA with Bonferroni’s post-hoc test: WT stimulated compared to WT 
unstimulated (***p < 0.001), GABA-Cnr1-/- stimulated compared to GABA-Cnr1-/-  unstimulated 
(***p < 0.001, *p < 0.05). Genotype effect for TNFα production when unstimulated WT and GABA-
Cnr1-/-  are compared (++p < 0.01). Values represent mean ± SEM; n = 6 per group. 
 
After 48h of LPS stimulation, one-way ANOVA revealed a significant LPS treatment effect in IL1β 
(F(3, 30) = 6.854, p < 0.01) and  IL-6  (F(3, 20) = 5.752, p < 0.001) and in  TNFα (F(3, 20) = 7.983, p 
< 0.01). IL1β production in stimulated WT was higher than in WT unstimulated (p < 0.05) and 
stimulated GABA-Cnr1-/- was higher than in unstimulated GABA-Cnr1-/-  group (p < 0.01). IL-
6 production was also significantly changed when WT stimulated and WT unstimulated 
A Cytokine production in OHSC after 24h stimulation with 5mg/ml LPS 
0
200
400
600
800
1000
IL
1
b
 (
p
g
/m
l)
*** ***
0
200
400
600
800
1000
IL
6
 (
p
g
/m
l)
*** ***
WT
WT LPS
GABA-Cnr1-/- 
GABA-Cnr1-/- LPS0
200
400
600
800
T
N
F
a
 (
p
g
/m
l) ***
*
++
Results 44 
controls were compared (p < 0.05), but stimulated GABA-Cnr1-/- group showed even higher 
IL-6 level compared to unstimulated GABA-Cnr1-/- group (p < 0.01). TNFα production was 
equally increased in both stimulated WT and stimulated GABA-Cnr1-/-   as compared to 
unstimulated GABA-Cnr1-/-  and WT controls groups (p < 0.01). Figure 4.1.1B.   
Figure 4.1.1B: ELISA measurement of OHSC supernatants for cytokine release after 48h LPS 
stimulation. Stimulation with LPS for 48h led to increased production of IL1β, IL-6 and TNFα 
irrespective of genotype.  IL1β and IL-6 production was even higher in stimulated GABA-Cnr1-/- 
group. One-way ANOVA with Bonferroni’s post-hoc test:  *p< 0.05,**p < 0.01. Values represent 
mean± SEM; n =3-6 per group. 
 
When LPS treatment effect was assessed after 72h of stimulation, one-way ANOVA showed a 
significant LPS treatment effect in IL1β (F(3, 45) = 4.887, p < 0.01),   IL-6  (F(3, 20) = 14.16, p < 0.001) 
and TNFα (F(3, 20) = 9.015, p < 0.001). IL1β production in stimulated WT was not significantly 
higher than in WT unstimulated (p > 0.05), while  stimulated GABA-Cnr1-/- showed 
significantly increased IL1β compared to unstimulated  GABA-Cnr1-/-  group (p < 0.001). IL-6 
production was not significantly changed when WT stimulated and WT unstimulated controls 
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were compared (p > 0.05), but stimulated GABA-Cnr1-/- group showed higher IL-6 level 
compared to unstimulated GABA-Cnr1-/- group (p < 0.001). TNFα production was higher in 
stimulated GABA-Cnr1-/- compared to unstimulated GABA-Cnr1-/- group (p < 0,01), while 
there was no significant change in TNFα level in the WT groups (p < 0.05). Stimulated GABA-
Cnr1-/-  samples revealed significantly higher production of  IL1β (p < 0.01),  IL-6 (p < 0.001) 
and TNFα (p < 0.001) compared to stimulated WT samples. Figure 4.1.1C.    
 
Figure 4.1.1C: ELISA measurement of OHSC supernatants for cytokine release after 72h LPS 
stimulation. Stimulation with LPS for 72h led to significantly increased production of IL1β, IL-6 and 
TNFα only in stimulated GABA-Cnr1-/- group.  One-way ANOVA with Bonferroni’s post-hoc test:  
Treatment effect: **p< 0.01;***p < 0.001. Genotype effect: ++p < 0.01; +++ p < 0.001. Values represent 
mean± SEM; n =3 per group. 
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4.1.2 Multiple intraperitoneal LPS injection leads to altered microglia reactivity in 
GABA-Cnr1-/- mice 
 
Neuron-glia interaction is crucial in the regulation of inflammation responses in the CNS. 
Perturbed neuron-glial communication as a result of a disturbed cannabinoid system activity 
may affect microglia response to acute insult, here, a single LPS injection. Microglial response 
to an incessant (chronic) insult, here multiple LPS injection, may also change, leading to an 
altered cytokine production and/or microgliosis. We tested this hypothesis in a GABAergic 
neuron-specific Cnr1 knockout model. 
 
Figure 4.1.2: Representative depiction of microglia density in the hippocampus. The length of 
the scale bar is 200 μm. 
 
Microglial density increased after single intraperitoneal (i.p) LPS injection in both WT control 
and GABA-Cnr1-/- mice. Two-way ANOVA showed that there was a significant treatment 
effect (F(1, 8) = 23.01, p < 0.01; Fig. 4.1.2.1A) and genotype effect (F(1, 8) = 10.81, p < 0.05; Fig. 
4.1.2.1A). No interaction between treatment and genotype was seen (F(1, 8) = 0.1971, p > 0.05; 
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Fig. 4.1.2.1A). After multiple i.p injection, similar to after single injection, significant treatment 
effect (F(1, 8) = 45.92, p < 0.001; Fig. 4.1.2.1B), and genotype effect (F(1, 8) = 25.41, p < 0.01; 
Fig. 4.1.2.1B) was revealed. As in the previous test, the interaction between treatment and 
genotype was not significant (F(1, 8) = 1.546, p > 0.05; Fig. 4.1.2.1B). 
 
Figure 4.1.2.1: Microglia reactivity in terms of density is stronger in GABA-Cnr1-/- and even 
strongest after multiple injection. (A) Single LPS treatment led to a significantly increased microglia 
number in WT and GABA-Cnr1-/-mice as compared to their untreated counterparts (*p < 0.05). (B) 
Multiple LPS treatment led to increased microglia number in the hippocampus of treated WT when 
compared to untreated WT mice (++p < 0.01). The increase was exacerbated when GABA-Cnr1-/-treated 
and untreated groups were compared (+++p < 0.001). Analysis was performed by two-way ANOVA 
followed by Bonferroni’s post hoc test. Lines represent mean value; n = 3 per group. 
 
Next we sought to understand whether the exacerbated microglial reactivity in the GABA-Cnr1-
/- mice after LPS treatment, as observed in the increased microglia density, is reflected in the 
levels of production of prominent pro-inflammatory cytokines like IL-6, IL-1β and TNF-α. RT-
PCR was performed with the brains of single and multiple injected mice and their WT 
littermates. 
Following single and multiple LPS injection, there was significant decrease in IL-6 production 
in the single injected mice (F(1, 27) = 15.35, p < 0.001; Fig. 4.1.2.2A) but not in the multiple 
injected mice (F(1, 20) = 3.876, p > 0.05; Fig. 4.1.2.2B). No genotype effect was observed (F(1, 
27) = 0.3778, p > 0.05; Fig. 4.1.2.2A) for single injection and (F(1, 20) = 0.0630, p > 0.05; Fig. 
4.1.2.2B) for multiple injection. Bonferroni’s multiple comparison test showed that after single 
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injection, IL-6 production decreased significantly in the treated WT group as compared to the 
untreated WT control group (p < 0.05). This effect was exacerbated in the treated GABA-Cnr1-
/- group compared to untreated GABA-Cnr1-/- group (p < 0.01). IL-1β production was 
significantly increased after LPS treatment with treatment effect observed to be (F(1, 28) = 52.93, 
p < 0.0001; Fig. 4.1.2.2C) for single injected and (F(1, 20) = 96.39, p < 0.0001; Fig. 4.1.2.2D) for 
multiple injected. There was no significant genotype effect (F(1, 28) = 0.1281, p > 0.05; Fig. 
4.1.2.2C) for single injected group and (F(1, 20) = 0.01402, p > 0.05; Fig. 4.1.2.2D) for multiple 
injected group. Bonferroni’s multiple comparison test indicated that single LPS injection led to 
significantly increased IL-1β production in the treated WT group as compared to the untreated 
WT control group (p < 0.0001) in both single and multiple injection paradigms. This effect was 
similar in the treated GABA-Cnr1-/- group when compared to untreated GABA-Cnr1-/- group (p 
< 0.0001). After single LPS treatment, TNF-α production increased significantly (F(1, 27) = 
45.06, p < 0.0001; Fig. 4.1.2.2E) and after multiple injection the treatment effect was also 
significant at (F(1, 27) = 12.83, p < 0.01; Fig. 4.1.2.2F). No genotype effect was observed in any 
of the groups (F(1, 20) = 0 .7159, p > 0.05; Fig. 4.1.2.2). Bonferroni’s multiple comparison test 
showed that single LPS injection led to significantly increased TNF-α production in the treated 
WT group as compared to the untreated WT control group (p < 0.001). The same effect was 
recorded in the treated GABA-Cnr1-/- group when compared to untreated GABA-Cnr1-/- group 
(p < 0.001). Whereas, after multiple injection, TNF-α production significantly increased in the 
treated WT group as compared to the untreated WT control group (p < 0.01), but not in the 
treated GABA-Cnr1-/- group when compared to untreated GABA-Cnr1-/- group (p > 0.05). 
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Figure 4.1.2.2: Gene expression of IL-6, IL1β and TNF-α are differentially altered after LPS 
treatment of GABA-Cnr1-/- mice. LPS treatment led to a decreased production of IL-6 in WT as well 
as in GABA-Cnr1-/- mice after single injection; Two-way ANOVA with Bonferroni’s post-hoc test:  p > 
0.05, *p< 0.05, **p < 0.01.IL-1β increased dramatically irrespective of treatment paradigm and 
genotype; Two-way ANOVA with Bonferroni’s post-hoc test: ****p < 0.0001. Two-way ANOVA with 
Bonferroni’s post-hoc test revealed that TNF-α increased after single injection irrespective of genotype 
(***p < 0.001) but in the multiple injection paradigm, it only increased in WT treated group (**p < 
0.01), not the GABA-Cnr1-/-  group (p > 0.05).Values represent mean ± SEM; n = 6 - 8 per group.  
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4.1.3 Sickness behaviour and microglia reactivity to intracerebroventricular (ICV) 
LPS injection  
 
After ascertaining microglia reactivity to intraperitoneal LPS in GABA-Cnr-/- mice, we sought 
to investigate microglia reactivity after direct injection of LPS into the brain (ICV). 
Furthermore,  the role of ageing and its possible correlation to sociability of the mice were 
tested. 
We assessed sickness behaviour as reduced motility and social preference. 2-way ANOVA 
revealed no significant genotype related change in motility of 2 months old mice (genotype 
effect: F(1, 45) = 1.578, p > 0.05; Fig. 4.1.3.1A).  Treatment with LPS significantly reduced the 
motility of 2 months old mice (Treatment effect: F(1, 44) = 4.121, p < 0.05; Fig. 4.1.3.1A)  Hence, 
there was no interaction between genotype and treatment (Treatment x genotype: F(1, 45)= 0 
.09699, p > 0.05; Fig. 4.1.3.1A). Social preference, which is assessed as a difference between 
the interaction time with an object or a partner mouse, was highly significant in 2 months old 
WT mice as mice interacted more with a partner mouse as with an object (F(1, 44) = 27.18, p < 
0.001; Fig. 4.1.3.1A). Furthermore, untreated WT mice spent more time investigating the 
partner mouse as compared to the time spent by LPS treated WT mice investigating a partner 
mouse (Treatment effect: F(1, 44) = 4 .121, p < 0.05; Fig. 4.1.3.1A). GABA-Cnr1
-/- mice also 
showed a strong preference for the partner mouse (F(1, 44) = 18.52, p < 0.001; Fig. 4.1.3.1A) 
with no significant treatment effect observed ( Treatment effect: F(1, 44) = 2 .037, p > 0.05; Fig. 
4.1.3.1A). 
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Figure 4.1.3.1A: LPS treatment led to sickness behaviour in 2 months old WT mice, but not in 2 
months old GABA-Cnr1-/- mice. Preference for partner mice was significantly higher in untreated WT 
mice as compared to treated WT. Preference for partner mice was the same for both treated and untreated 
GABA-Cnr1-/- mice. Two-way ANOVA with Bonferroni’s post-hoc test: p > 0.05;  **p < 0.05; **p < 
0.01; ***p < 0.001.Values represent mean ± SEM; n = 12 per group. 
 
In 12 months old mice, the distance travelled was significantly reduced in LPS treated groups 
(Treatment effect: F(1, 46) = 4 .469, p < 0.05; Fig. 4.1.3.1B) in both genotypes (Genotype effect: 
F(1, 46) = 1 .722, p > 0.05; Fig. 4.1.3.1B). Preference for a partner mouse was similarly strong in 
both WT and GABA-Cnr1-/-  mice (F(1, 46) = 14.83, p < 0.001; Fig. 4.1.3.1B) for WT and (F(1, 46) 
= 20.83, p < 0.001; Fig. 4.1.3.1B) for transgenic mice. After LPS treatment, preference for a 
partner mouse was reduced in both genotypes (F(1, 46) = 0.3753, p > 0.05; Fig. 4.1.3.1B) for WT 
and (F(1, 46) = 0.2874, p > 0.05; Fig. 4.1.3.1B)  for GABA-Cnr1-/- .  
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Figure 4.1.3.1B: LPS treatment elicited similar sickness behaviour in 12 months old WT and 
GABA-Cnr1-/- mice. Mice mobility was reduced after LPS treatment in both genotypes.  Preference for 
partner mice was decreased in LPS-treated mice. The preference for a partner mouse over an object was 
highly significant in both genotypes. Two-way ANOVA with Bonferroni’s post-hoc test: p > 0.05;    **p 
< 0.01; ***p < 0.05.Valuesrepresentmean±SEM; n = 12- 13 per group. 
 
The distance travelled by 18 months old mice, was not significantly reduced in LPS treated 
groups compared to the untreated groups (Treatment effect: F(1, 30) = 3 .18, p > 0.05; Fig. 
4.1.3.1C). There was also no genotype effect (F(1, 30) = 2 .279, p > 0.05; Fig. 4.1.3.1C). 
Interaction between genotype and treatment was not significant (F(1, 30) = 1.9, p > 0.05; Fig. 
4.1.3.1C).  Preference for a partner mouse was significantly high for both WT and GABA-Cnr1-
/-  mice (F(1, 30) = 16.4, p < 0.001; Fig. 4.1.3.1C) for WT and (F(1, 30) = 13.81, p < 0.001; Fig. 
4.1.3.1C) for transgenic mice. There was a significant LPS treatment induced decrease in 
partner preference in the treated WT and transgenic mice ( p < 0.05; Fig. 4.1.3.1C). Untreated 
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WT and GABA-Cnr1-/-  mice maintained a strong preference for a partner over an object (p < 0.01) for 
WT and (p < 0.001) for GABA-Cnr1-/-  mice. Fig. 4.1.3.1C. 
 
Figure 4.1.3.1C: LPS treatment led to sickness behaviour in 18 months old WT and GABA-Cnr1-
/- mice. Mice mobility was not significantly reduced after LPS treatment in both genotypes.  Preference 
for partner mice was significantly reduced in treated mice as compared to untreated mice. While 
preference for a partner mouse over an object was highly significant in both genotypes. Two-way 
ANOVA with Bonferroni’s post-hoc test: p > 0.05; **p < 0.01; ***p < 0.05. Values represent mean 
±SEM; n = 7- 10 per group. 
 
After showing that ICV-LPS treatment effects lead to sickness behaviour as evident in the 
reduced sociability in both genotypes, we investigated whether the sickness behaviour can be 
traced back to increased microglia reactivity as a result of increasing microglia density in the 
hippocampus.   
Two-way ANOVA showed that the density of microglia in the hippocampus is significantly 
increased in 2-month-old mice after LPS treatment (F(1, 8) = 18 .14, p < 0.01; Fig. 4.1.3.2A). 
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Microglia density differed between the genotypes (F(1, 8) = 15.9, p < 0.01; Fig. 4.1.3.2A),  no 
treatment x genotype interaction was detected (F(1, 8) = 0.8786, p > 0.05; Fig. 4.1.3.2A). 
However, Bonferroni’s multiple comparison test revealed that while LPS treatment led to a 
significantly higher microglia density in the WT (p < 0.05), there was no significant change in 
the GABA-Cnr1-/-  animals (p > 0.05). Additionally, there was a significantly higher density of 
microglia present in hippocampus of untreated GABA-Cnr1-/-  animals compared to their 
untreated WT siblings (p < 0.05). This genotype effect was not seen in the treated groups (p > 
0.05). Figure 4.1.3.2A. 
Analysis of 12 months old mice resulted also in a significant treatment effect (F(1, 8) = 20 .97, p 
< 0.01; Fig. 4.1.3.2B)  and  genotype effect (F(1, 8) = 23 .56, p < 0.01; Fig. 4.1.3.2B).  
Bonferroni’s multiple comparison test now revealed that LPS treatment led to a significantly 
higher microglia density in both WT and GABA-Cnr1-/- groups (p < 0.05). Furthermore, 
microglia density was significantly higher in untreated and treated GABA-Cnr1-/- groups 
compared to WT of similar treatment (p < 0.05).  
In the 18 months old mice groups, LPS treatment effect was highly significant (F(1, 8) = 57.26, 
p < 0.001; Fig. 4.1.3.2C), and also the genotype effect was significant (F(1, 8) = 16.45, p < 0.01; 
Fig. 4.1.3.2C). However, Bonferroni’s multiple comparison test revealed that, while LPS 
treatment led to an exacerbated increase in of microglia density in the GABA-Cnr1-/- group (p 
< 0.001), this was only slightly significant in the WT group (p < 0.05). Consequently, the 
microglia density in treated GABA-Cnr1-/- animals was significantly higher than in their treated 
WT siblings (p < 0.001). There was no significant genotype-related change in the untreated 
groups (p > 0.05). Figure 4.1.3.2C. 
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Figure 4.1.3.2: LPS treatment associated increase in microglia density in the hippocampus was 
age-dependent in GABA-Cnr1-/- mice. (A) ICV-LPS treatment led to a significantly increased 
microglia density in the treated 2 months old WT mice as compared to untreated WT mice (*p < 0.05). 
There was no significant change in microglia density when the 2 months old treated and untreated 
GABA-Cnr1-/- groups are compared (p > 0.05). The density of microglia in the hippocampus of untreated 
GABA-Cnr1-/-  animals was higher than in the untreated WT siblings (+p < 0.05).  (B) In the 12 months 
old groups, LPS treatment led to similarly increased microglia density in the hippocampus of both 
treated WT and GABA-Cnr1-/- groups when compared to untreated WT and GABA-Cnr1-/-groups, 
respectively (*p < 0.05). Treated and untreated GABA-Cnr1-/-  animals showed significantly increased 
microglia density compared to WT littermates of similar treatment (+p < 0.05). (C) Microglia density in 
the hippocampus of treated WT 18 months old mice was significantly increased compared to untreated 
WT (*p < 0.05). The treatment effect was exacerbated in GABA-Cnr1-/- animals (***p < 0.001). The 
density of microglia in treated GABA-Cnr1-/- animals was significantly increased compared to treated 
WT group (++p < 0.01). Analysis was performed by two-way ANOVA followed by Bonferroni’s post 
hoc test. Horizontal lines represent mean value; n = 3 per group. 
 
Next, we sought to elucidate the role attributed to the morphological changes of microglia 
observed in the hippocampus. Hence, we analysed the cytokine expression levels in the 
different genotype and age groups, treated and untreated. Two-way ANOVA revealed that LPS 
treatment effect on IL-1β expression was significant in the 2 months old groups (F(1, 39) = 18 
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.57, p < 0.001; Fig. 4.1.3.3A), while there was no significant genotype effect (F(1, 39) = 0.02796, 
p > 0.05; Fig. 4.1.3.3A) and no age x genotype interaction (F(1, 39) = 0.0092, p > 0.05; Fig. 
4.1.3.3A). Bonferroni’s post hoc test showed that LPS treatment led to a similarly increased IL-
1β expression in the treated WT compared to untreated WT mice (p < 0.01) and in the treated 
GABA-Cnr1-/-  compared to untreated GABA-Cnr1-/-  mice (p < 0.01). IL-1β expression in the 
12 months old mice was affected by LPS treatment F(1, 36) = 10.79, p < 0.01; Fig. 4.1.3.3A). No 
genotype effect was attained (F(1, 36) = 1.106, p > 0.05; Fig. 4.1.3.3A) and interaction between 
treatment and genotype was not significant (F(1, 36) = 1.272, p > 0.05; Fig. 4.1.3.3A). 
Bonferroni’s post hoc test, however, revealed a significant increase in IL-1β expression in the 
treated WT group compared to untreated WT group (p < 0.01) but not in the  GABA-Cnr1-/-  
group. LPS treatment induced IL-1β expression was highly significant in 18 months old mice 
(F(1, 27) = 31.94, p < 0.0001; Fig. 4.1.3.3A), but no significant genotype effect or interaction was 
obtained (F(1, 27) = 0.0084, p > 0.05; Fig. 4.1.3.3A) and (F(1, 27) = 0.085, p > 0.05; Fig. 4.1.3.3A). 
Bonferroni’s multiple comparison test showed a significantly increased IL-1β expression in the 
treated WT group compared to untreated WT group (p < 0.01) and an even higher significant 
when treated  GABA-Cnr1-/-  group was compared to untreated GABA-Cnr1-/-  group (p < 
0.001). 
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Figure 4.1.3.3A: LPS treatment led to an increased IL-1β expression in each age group of the WT 
mice, whereas the effect of LPS was age-dependent in GABA-Cnr1-/-. IL-1β expression after ICV-
LPS treatment was stably increased in WT mice across all age groups (**p < 0.01). The expression of 
IL-1β in GABA-Cnr1-/- mice was significantly increased in treated 2 months old group (**p < 0.01) and 
then not significant in 12-month-old mice (p > 0.05) to be highly significant in 18 months old mice 
group (***p < 0.001). Analysis was performed by two-way ANOVA followed by Bonferroni’s post hoc 
test and values represent mean ±SEM; n = 7 - 11 per group. 
 
For IL-6 expression in 2 months old mice groups, two-way ANOVA showed that there was no 
treatment effect (F(1, 39) = 3.571, p > 0.05; Fig. 4.1.3.3B), no genotype effect (F(1, 39) = 2.722, p 
> 0.05; Fig. 4.1.3.3B) and no interaction between treatment and genotype (F(1, 39) = 0.1701, p > 
0.05; Fig. 4.1.3.3B). Bonferroni’s multiple comparison test showed no significant change in 
IL–6 expression in all groups, treated and untreated (p > 0.05). In the 12 months old mice 
groups, LPS led to a significant treatment effect (F(1, 36) = 7.391, p < 0.05; Fig. 4.1.3.3B). No 
genotype effect (F(1, 36) = 1.647, p > 0.05; Fig. 4.1.3.3B) or interaction effect (F(1, 36) = 2.64, p > 
0.05; Fig. 4.1.3.3B) was obtained. Bonferroni’s multiple comparison test revealed that while 
IL–6 expression  was significantly increased in treated WT mice group compared to untreated 
WT group (p < 0.01), treated GABA-Cnr1-/-  group did not produce a significantly higher IL-6 
as compared to untreated GABA-Cnr1-/-  group (p > 0.05). Two-way ANOVA revealed a 
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significant LPS treatment effect in IL-6 expression of 18 months old mice groups (F(1, 26) = 
5.627, p < 0.05; Fig. 4.1.3.3B). There was no genotype effect or interaction (F(1, 29) = 0.0855, p 
> 0.05; Fig. 4.1.3.3B) and (F(1, 29) = 0.0333, p > 0.05; Fig. 4.1.3.3B), respectively.  
 
Figure 4.1.3.3B: LPS treatment did not lead to a generally increased IL-6 expression. IL-6 
expression after ICV-LPS treatment was not significantly increased in GABA-Cnr1-/- mice regardless of 
age (p > 0.05). IL-6 expression was not significantly increased in 2 months old WT and GABA-Cnr1-/-  
mice both in  the treated groups (p > 0.05). Treated 12 months old WT but not GABA-Cnr1-/- mice group 
produced significantly higher IL-6 compared to untreated (**p < 0.01). In 18 months old mice, IL-6 
production in both treated groups was enhanced compared to untreated groups (*p < 0.05). Analysis was 
performed by two-way ANAOVA followed by Bonferroni’s post hoc test and values represent mean 
±SEM; n = 8 - 10 per group. 
 
After two-way ANOVA analysis, it was obtained that ICV-LPS treatment of 2 months old mice 
resulted in a significant treatment effect on TNF-α expression (F(1, 34) = 14.66, p < 0.001; Fig. 
4.1.3.3C), whereas, no significant genotype effect nor interaction was seen (F(1, 34) = 0.1645, p 
> 0.05; Fig. 4.1.3.3C) and (F(1, 34) = 0.4268, p > 0.05; Fig. 4.1.3.3C) for genotype and interaction 
respectively. Bonferroni’s multiple comparison test further showed that LPS treatment led to a 
significant increase in TNF- expression only in the WT groups (p < 0.01) but not in the 
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GABA-Cnr1-/-  groups (p > 0.05). TNF-α expression in 12 month old mice was significantly 
increased after LPS treatment (F(1, 36) = 16.08, p < 0.001; Fig. 4.1.3.3C). No significant genotype 
effect (F(1, 36) = 0.000, p > 0.05; Fig. 4.1.3.3C) nor interaction (F(1, 36) = 0.0555, p > 0.05; Fig. 
4.1.3.3C) was seen. Bonferroni’s multiple comparison test revealed that LPS treatment let to a 
significant increase in TNF- expression in the WT groups (p < 0.05) and also in the GABA-
Cnr1-/-  groups (p > 0.01). Now, in the 18 months old mice, treatment effect after two-way 
ANOVA for TNF-α expression was obtained to be highly significant  (F(1, 28) = 33.76, p < 
0.0001; Fig. 4.1.3.3C). No significance was obtained for genotype effect (F(1, 28) = 0.2121, p > 
0.05; Fig. 4.1.3.3C) and no significant interaction was observed (F(1, 28) = 0.0521, p > 0.05; Fig. 
4.1.3.3C). Bonferroni’s post hoc test also showed  a significant LPS treatment effect for both 
genotypes. 
Figure 4.1.3.3C: LPS treatment led to a relatively stable increased of TNF-α production in   WT 
mice but increased in GABA-Cnr1-/- mice in an age- dependent manner. TNF-α expression after 
ICV-LPS treatment was stably increased in WT mice across all age groups (**p < 0.01). The expression 
of TNF-α in GABA-Cnr1-/- mice did significantly increase in the treated groups in an age-dependent 
manner (**p < 0.01 and ***p < 0.001). Analysis was performed by two-way ANOVA followed by 
Bonferroni’s post hoc test and values represent mean ±SEM; n = 7 - 10 per group. 
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4.1.4 Increased lipofuscin accumulation in isolated microglia of older GABA-Cnr1-/- 
mice 
 
Increasing lipofuscin content of a cell has been reported to correlate with advancing age, as the 
clearance mechanism in cells is weakened, leading to accumulation of lysosomal degradation 
products with autofluorescence property at wavelengths around 400 to 560 nm. These 
accumulated complex of misfolded and oxidized proteins, as well as lipids,  influence microglia 
reactivity, resulting in age-related microglia senescence as observed in progressing aging (Hartl 
et al., 2011; Mizushima et al., 2008). Here, we wanted to elucidate the role of GABAergic 
neuron-specific CB1 receptor knockout in microglial lipofuscin accumulation as an indication 
for early onset of aging. 
In a set of FACS experiments, using microglia autofluorescence from 2 months old WT 
littermates as a base line, the number of cells containing lipofuscin was measured at 488 nm 
(FITC) in 2 and 12 months old GABA-Cnr1-/- mice as well as 12 months old WT littermates. 
ANOVA analysis revealed no significant genotype effect (F(1, 23) = 2.171, p > 0.05; Fig. 4.1.4A). 
There was, however a significant age effect (F(1, 23) = 55.82, p < 0.0001; Fig. 4.1.4A). No 
significant age-genotype interaction effect was observed (F(1, 23) = 0.9676, p > 0.05; Fig. 
4.1.4A). Lipofuscin autofluorescence measurement at 561 nm (PE) showed no significant 
genotype effect (F(1, 23) = 2.211, p > 0.05; Fig. 4.1.4B). Again a significant age effect was 
reached (F(1, 23) = 109.3, p <  0.0001; Fig. 4.1.4B) and no significant age-genotype interaction 
effect was observed (F(1, 23) = 0.1188, p > 0.05; Fig. 4.1.4B). Lastly, lipofuscin accumulation 
measured at 496 nm (PerCP-Cy5.5) revealed a significant genotype effect (F(1, 23) = 10.93, p < 
0.01; Fig. 4.1.4C) and a significant age effect (F(1, 23) = 199.3, p <  0.0001; Fig. 4.1.4C). Here, 
the age-genotype interaction effect was significant (F(1, 23) = 6.345, p < 0.05; Fig. 4.1.4C). 
Bonferroni’s post hoc test revealed that there was a significant genotype effect between the 12 
months old groups (p < 0.01) but not in the 2 months old groups (p= ns).  
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Figure 4.1.4: Lipofuscin accumulation was exacerbated in 12 months old GABA-Cnr1-/- mice 
compared to age-matched WT littermates. Lipofuscin accumulation was significantly increased in 12 
months old mice groups at all three wavelengths measured (****p < 0.0001). A genotype attributed 
increase in lipofuscin accumulation was significant only in 12 months old mice measured at 496 nm 
(**p < 0.01). An age-genotype interaction effect was also significant for measurement at wavelength 
496 nm. Analysis was performed by two-way ANOVA followed by Bonferroni’s post hoc test and 
values represent mean ±SEM; n = 8 - 12 per group. 
 
4.2 Neuron-microglial bidirectional regulation 
 
4.2.1 Impaired neuroimmune regulators (NIReg) expression in hippocampus of 
microglia-specific Dagla-/- mice 
 
After establishing that the deletion of a component of the endocannabinoid system, here CB1 
receptor on GABAergic neurons, is enough to induce senescence-related characteristics in 
microglia, we asked whether this was due to deregulated interaction between neurons and 
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microglia, leading to reduced neuronal control. Hence, we investigated the expression of two 
major neuroimmune regulator proteins pairs (CD200/CD200R and CX3CL1/CX3CR1) in the 
hippocampus of microglia-specific Dagla-/- mice. In a previous experiment performed in our 
lab, we already found out that the expression of neuroimmune regulators are differentially 
changed during ageing. CD200 and CD200R expression was decreased in the hippocampus in 
WT 12 months old mice (p < 0.001) for CD200 and (p < 0.05) for CD200R compared to their 
age-matched GABA-Cnr1-/- siblings. Although CX3CL1 expression was unchanged in 12 
months old WT mice during ageing, GABA-Cnr1-/-  animals in similar age showed an increased 
expression (p < 0.01). CX3CR1 expression was not changed during ageing neither in the WT 
nor in the GABA-Cnr1-/-  animals. (Bachelor project, Till Zimmer, 2013). We, thus, asked 
whether these changes were reproducible if another component of the endocannabinoid system, 
here Daglα on microglia, is altered.  
 
4.2.1C: Representative micrographs of CD200 and CD200R immunostainings in the 
hippocampus of WT and Dagl-/-  mice. The length of the scale bar is 500 μm 
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4.2.1D: Representative micrographs of CX3CL1 and CX3CR1 immunostainings in the 
hippocampus of WT and Dagl-/-  mice. The length of the scale bar is 500 μm 
 
Immunohistological experiments showed that protein levels of CD200 ligand produced by 
neurons and the corresponding CD200R on microglia are not significantly different in 2 months 
old WT and Dagla-/- mice (U = 20, p > 0.05; Fig. 4.2.1A) and (U = 26, p > 0.05; Fig. 4.2.1A) 
for CD200 and CD200R respectively. There was also no significant difference in fractalkine 
(CX3CL1) and fractalkine receptor (CX3CR1) in 2 months old WT and Dagla
-/- mice (U = 54, 
p > 0.05; Fig. 4.2.1B) and (U = 70, p > 0.05; Fig. 4.2.1B) for CX3CL1 and CX3CR1 respectively. 
However, in 12 months old mice groups, CD200 and CD200R protein levels were significantly 
higher in Dagla-/- mice as compared to WT littermates (U = 18, p < 0.05; Fig. 4.2.1A) and (U = 
6, p < 0.0001; Fig. 4.2.1A) for CD200 and CD200R respectively. Similarly, CX3CL1 and 
CX3CR1 protein levels were significantly higher in Dagla
-/- mice as compared to WT littermates 
(U = 12, p < 0.01; Fig. 4.2.1B) and (U = 23, p < 0.05; Fig. 4.2.1B) for CX3CL1 and CX3CR1 
respectively. 
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Figure 4.2.1: 12 months old Dagla-/- mice showed a significant upregulation of neuron-microglia 
communication proteins as compared to WT littermates.(A) CD200 and CD200R proteins were 
significantly increased in 12 months old Dagla-/- mice (Mann-Whitney U = 20 and 26, *p < 0.05, ****p 
< 0.0001,two tailed, values represent mean ± SEM, n = 9 - 12). (B) CX3CL1 and CX3CR1 proteins were 
significantly higher in 12 months old Dagla-/- mice as compared to WT (Mann-Whitney U = 12 and 23, 
**p < 0.01, *p < 0.05, two tailed, values represent mean ± SEM, n = 9 - 12).  
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4.2.2 Microglia-specific deletion of Dagla-/- led to upregulation of GABAergic receptors 
and pro-inflammatory cytokines in microglia of 12 months old mice 
 
Following up on our findings that some neuron-microglia communication proteins are 
upregulated in 12 months old microglia-specific Dagla-/- mice, we asked what role GABA 
signalling play in this communication cascade and whether a pro-inflammatory or rather an 
anti-inflammatory microglia profile is encouraged. We investigated expression profiles of a 
selected set of GABA receptors as well as pro-inflammatory and anti-inflammatory cytokines 
in isolated microglia. 
Expression levels of GABA B receptors and most important subunits of GABA A receptor 
(Gabbr1, Gabbr2, Gabra1, Gabrb2, Gabrg2 and Gabrd) were not significantly changed in both 
2 months old WT and microglia Dagla-/- mice (p > 0.05). Expression of pro-inflammatory 
cytokines (IL-1β) and anti-inflammatory cytokine (IL-10 and Fizz) were not significantly 
altered (p > 0.05). Figure 4.2.2A. 
Figure 4.2.2A: GABA receptors expression and cytokine levels were not altered in 2 months old 
microglia specific Dagla-/- mice. 
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In 12 months old microglia specific Dagla-/- mice, expression of Gabrb2 (t = 2.95, p < 0.05; Fig. 
4.2.2B), Gabrg2 (t= 2.94, p < 0.05; Fig. 4.2.2B) and Gabrd (t = 2.94, p < 0.05; Fig. 4.2.2B) 
were significantly increased as compared to WT littermates. Expression levels of cytokine 
proteins were also significantly increased (t = 3.06, p < 0.05; Fig. 4.2.2B) and (t = 2.75, p < 
0.05; Fig. 4.2.2B) for IL-1β and Fizz respectively. 
Figure 4.2.2B: Some GABA receptors expression profile and cytokines levels were significantly 
increased in 12 months old microglia specific Dagla-/- mice (*p < 0.05). 
 
4.3 Cognitive ageing and microglia reactivity in microglia-specific 
Dagla-/- mice 
 
As previously stated, a deletion of CB1, resulting in a disturbance of the endocannabinoid 
system, leads to early onset of aging and increased microglia reactivity. Here, we sought to 
understand whether the deletion of Dagla on microglia cells alone is sufficient to induce 
enhanced neuroinflammation and age-related cognitive and social deficits as observed in the 
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CB1 knockout mouse model. A microglia specific Dagla-/- mouse line and their wild-type 
siblings were used in these experiments. 
4.3.1 Effects of a decreased microglial 2-AG production on the onset of recognition 
deficits 
  
Sociability 
In a longitudinal partner recognition test experiment, reduced 2-AG production in microglia-
specific Dagla-/-male mice did not affect the preference for a partner mouse over an object as 
both knockout mice and their wild-type siblings showed a similar strong significant preference 
for partner mice (U= 13, p < 0.001; Fig. 4.3.1.1A,B), which remained similar when the mice 
were 12 months old (U = 14, p <0.001; Fig. 4.3.1.1C,D).The total distance covered by the mice 
exploring their surrounding was similar regardless of genotype and age(U = 96, p > 0.05; Fig. 
4.3.1.1E,F). 
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Figure 4.3.1.1: Dagla-/- mice exhibited a normal social character. (A,B) Both young 2 months old 
Dagla-/- and WT sibling control mice showed a  strong preference for partner mice. The average time 
spent investigating the partner as opposed to an object was similar for both genotypes (Mann-Whitney 
U = 48, ***p < 0.001,two-tailed, values represent mean ± SEM, n = 13 – 17). (C,D) Mice when 12 
months old showed a similar significance as observed in the young age group (Mann-Whitney U = 14, 
***p < 0.001,two-tailed, values represent mean ± SEM, n = 12 – 17). (E,F) The total distance covered 
during exploration was similar for both genotypes and age groups with no significance (Mann-Whitney 
U = 96, p > 0.05, values represent mean ± SEM, n = 13 - 17). ns stands for not significant. 
 
Cognitive ability 
The ability to recognise a previous partner was tested in both young and old mice. In 2 months 
old knockout mice, the recognition ability was strongly significant (U = 25, p < 0.001; Fig. 
4.3.1.2B) but not in the wild-type littermates (U = 56, p > 0.05; Fig. 4.3.1.2A). When mice were 
12 months old, the recognition ability was significant in the WT mice (U = 37, p < 0.05; Fig. 
4.3.1.2C), while significance remained but less pronounced than in young ones in the knockout 
mice (U = 64, p < 0.01; Fig. 4.3.1.2D). Novelty preference was significantly higher in young 
microglia-specific Dagla-/- mice than in the age-matched wild-type littermate (U = 57, p < 0.05; 
Fig. 4.3.1.2E). There was no significance in novelty preference between mice of both genotypes 
when 12 months old (U = 94, p > 0.05; Fig. 4.3.1.2F) 
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Figure 4.3.1.2: A slightly reduced cognitive ability in 12 months old Dagla-/- mice. (A)Young wild-
type control mice did not show significant recognition ability (Mann-Whitney U = 56, p > 0.05, two 
tailed, values represent mean ± SEM, n = 13), (B) while there was a significant recognition ability in 
Dagla-/-  mice (Mann-Whitney U = 25, ***p < 0.001,two tailed, values represent mean ± SEM, n = 17).  
(C) At age 12 month old, recognition ability was significant in WT mice (Mann-Whitney U = 37, *p < 
0.05, two tailed, values represent mean ± SEM, n = 12). 12 months old knockout mice also showed a 
significant but reduced recognition ability (Mann-Whitney U = 64, **p < 0.01,two tailed, values 
represent mean ± SEM, n = 17). (E) In young 2 months old mice, there was a significant difference in 
novelty preference (Mann-Whitney U = 57, *p < 0.05, two tailed, values represent mean ± SEM, n = 13 
- 17). (F) There was no difference in novelty preference in 12 months old mice (Mann-Whitney U = 94, 
p > 0.05, two tailed, values represent mean ± SEM, n = 12 - 17). ns stands for not significant. 
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Next, we tested the effect of successive increase of intertrial duration on the cognitive ability 
of both WT and knockout 12-months-old mice. Test with 1 h intertrial interval revealed a 
similar significance in recognition ability for both wild-type controls and Dagla-/- mice  (U = 
37, p < 0.05; Fig. 4.3.1.3A,B). (C) After a 2 hours intertrial interval, no significance was 
recorded in Dagla-/- mice (U = 83, p > 0.05; Fig.4.3.1.3C), while the Wild-type littermates 
retained their significant recognition ability (U = 50, p < 0.05; Fig. 4.3.1.3D). Novelty 
preference decreased in  Dagla-/- mice  with increasing intertrial intervals  (Fig. 4.3.1.4) 
Figure 4.3.1.3: (A,B) After an hour intertrial interval, 12-months-old wild-type control mice and Dagla-
/-  mice showed a significant ability to recognise the previous mice (Mann-Whitney U = 37, *p < 0.05,two 
tailed, values represent mean ± SEM, n = 13 - 17). (C) At 2 hours intertrial interval, the wild-type control 
mice still recognised the previous mice (Mann-Whitney U = 50, *p < 0.05,two tailed, values represent 
mean ± SEM, n = 13), (D) while Dagla-/-  mice no longer show significant recognition of previous 
mice(Mann-Whitney U = 83, p > 0.05,two tailed, values represent mean ± SEM, n = 14). ns stands for 
not significant. 
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Figure 4.3.1.4: Novelty preference decreases in Dagla-/- mice with successive increase in intertrial 
time. 
 
4.3.2 Effects of a decreased microglial 2-AG production in age-related spatial 
learning and memory deficits  
 
Next, we tested the spatial learning ability and memory strength of female microglia-specific 
Dagla-/- mice alongside their wild-type siblings in the Morris water maze test. During the 
acquisition phase of MWM test (Fig. 4.3.2.-1A, 2A and 3A), we investigated, on the one hand, 
the spatial learning and memory consolidation abilities of the mice. On the other hand, we 
assessed in the reversal phase (Fig. 4.3.2.-1B, 2B and 3B) the learning flexibility of the mice. 
Meanwhile, the memory strength was tested in the probe trial as represented in figure 4.3.2.4.  
When learning ability and memory consolidation were tested in the acquisition phase, the 
escape latency was similar for the 2 months old mice irrespective of genotype (F(1.22) = 0.02544, 
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months old group (F(1.17) = 0.1889, p > 0.05; Fig. 4.3.2.1B). In both age groups, regardless of 
genotype, the time needed to find the platform significantly decreased with progressing training 
days (F(5.110) = 21.92, p < 0.001; Fig. 4.3.2.1A) and (F(5.85) = 11.77, p < 0.001; Fig. 4.3.2.1A) 
for 2 and 12 months old groups, respectively. Escape latency was similarly not effected by 
genotype during the reversal phase, where memory flexibility is tested. For the young mice 
(F(1.32) = 0.01, p > 0.05; Fig. 4.3.2.1B) and old mice (F(1.21) = 0.5215, p > 0.05; Fig. 4.3.2.1B). 
The mice also find the platform in the reversal phase quicker with increasing training days in 
the 2 month old (F(2.42) = 10.22, p < 0.001; Fig. 4.3.2.1B) and  in 12 month old mice (F(2.64) = 
9.002, p < 0.001; Fig. 4.3.2.1B) 
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Figure 4.3.2.1: Reduced microglia 2-AG production did not affect spatial learning and memory 
ability of microglia-specific Dagla-/- mice. Escape latencies during the acquisition and reversal trials 
are depicted in A and B, respectively. There was no significant genotype effect in any of the age groups 
p > 0.05. (two-way ANOVA followed by Bonferroni’s t-test;  n=12 per group). 
 
During the learning flexibility and memory consolidation phase, the distance covered by the 
mice was also evaluated. The path length was similar for both genotypes in the 2 months old as 
well as in the 12 months old mice. (F(1.22) = 1.491, p > 0.05; Fig. 4.3.2.2A) and (F(1.21) = 0.01, p 
> 0.05; Fig. 4.3.2.2A) for 2 and 12 months old groups, respectively. The path length in the 
reversal phase was also not different regardless of genotype and age group. F(1.32) = 0.01, p 
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>0.05; Fig. 4.3.2.2B) and (F(1.21) = 0.2905, p > 0.05; Fig. 4.3.2.2B) for 2 and 12 months old 
groups, respectively. 
 
Figure 4.3.2.2: Reduced microglia 2-AG production did not affect spatial learning ability of 
microglia-specific Dagla-/- mice. Path length during the acquisition and reversal phase are depicted in 
A and B, respectively. There was no significant genotype effect in any of the age groups p > 0.05. (two-
way ANOVA followed by  Bonferroni’s t-test;  n=12 per group). 
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Figure 4.3.2.3: Reduced microglia 2-AG production did not affect the swim speed of microglia-
specific Dagla-/- mice. The swim speed during the acquisition and reversal phase are presented in A and 
B, respectively. There was no significant genotype effect in any of the age groups p > 0.05. (two-way 
ANOVA followed by Bonferroni’s t-test;  n=12 per group). 
The probe trial, which is a measure of memory strength, led to similar results for both 
genotypes, as mice demonstrated a significant memory strength when they were 2 months old, 
by spending more time in the quadrant where the platform was (F(1.26) = 9.321, p > 0.01; Fig. 
4.3.2.4) 
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The significantly high memory strength displayed during the probe trial at age 2 months was 
lost when the mice became 12 months old (F(1.37) = 0.01, p > 0.05; Fig. 4.3.2.4). 
 
Figure 4.3.2.4: Both microglia-specific Dagla-/- mice and their wild-type littermates demonstrated 
an age-dependent loss of memory strength. Significance in memory strength of  2 months old mice 
in both genotypes.**p< 0.01. (two-way ANOVA followed by Bonferroni’s t-test;  n=12 per group). 
Reduced memory strength when mice were 12 months old. P > 0.05. (two-way ANOVA followed by 
Bonferroni’s t-test;  n=12 per group). 
 
4.3.3 Microglia reactivity in Dagla-/- mice 
 
In order to investigate the possible role of the pro-inflammatory cytokines (IL-1β, IL-6 and 
TNFα) in learning and memory deficits of Dagla-/- mice, we assessed the production of the 
aforementioned cytokines in organotypic hippocampal slice culture (OHSC) experiments. For 
these experiments, a LysM-Dagla-/- mice line was used because OHSC is difficult to perform with 
mice older than a week. The inducible line we used in the behavioural part could, therefore, not be used, 
since induction of the knockout can begin only when the mice are already one month old. The 
experiments were performed as detailed in the materials and methods part. 
One-way ANOVA revealed a significant LPS treatment effect in IL1β (F(3, 32) = 17.32, p < 0.001), IL-
6 (F(3, 32) = 12.34, p < 0.001) and no significant effect for TNFα (F(3, 8) = 3.961, p > 0.05) after 
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24h stimulation. Bonferroni’s multiple comparison test, however, revealed that the significant 
increase in IL1β, IL-6 and TNFα production after LPS treatment is only present when the WT 
groups are compared, for IL1β and IL-6 (p < 0.001), and for TNFα (p < 0.05). There was no 
significant LPS effect observed in the Dagla-/- groups. IL1β and IL-6  levels were already high 
the Dagla-/- groups with significant genotype effect observed when unstimulated   Dagla-/-  mice 
are compared to their unstimulated WT siblings (p < 0.001). (Figure 4.3.3A) 
 
Figure 4.3.3A: ELISA measurement of OHSC supernatants for cytokine release after 24h LPS 
stimulation. Stimulation with LPS for 24h led to increased production of IL1β, IL-6 and TNFα in 
the WT groups (***p < 0.001; *p < 0.05) but not in the Dagla-/- OHSCs. IL1β and IL-6 levels were 
higher in the Dagla-/-  groups even without LPS treatment; genotype effect between unstimulated 
groups ( +++p < 0.001). One-way ANOVA with Bonferroni’s post-hoc test, values represent mean± 
SEM; n = 9 per group. 
 
After 48h of stimulation, LPS stimulation did result in increase production of any of the 
cytokines tested. (Treatment effect: F(3, 32) =  2.101, p > 0.05; F (3, 32) =  2.286,p > 0.05 and F(3, 
8) =  0.5097, p > 0.05 for IL1β, IL-6 and TNFα respectively. Bonferroni’s multiple comparison 
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test, nonetheless, showed a slightly significant increase in IL1β and IL-6 when WT groups 
stimulated and unstimulated were compared (p < 0.05). Figure 4.3.3B. 
 
 
Figure 4.3.3B: ELISA measurement of OHSC supernatants for cytokine release after 48h LPS 
stimulation. Stimulation with LPS for 48h led to an increase in production of IL1β and IL-6  only in 
the WT group (*p < 0.05). One-way ANOVA with Bonferroni’s post-hoc test, values represent mean 
± SEM; n = 9 per group. 
 
Now, after 72h of stimulation, LPS stimulation resulted in increase production of only IL1β 
(F(3, 32) =  6.372, p > 0.01). No significance was recorded for IL-6 (F (3, 32) = 0.8908, p > 0.05) 
and TNFα (F(3, 8) =  0.6778, p > 0.05). Bonferroni’s multiple comparisons test showed a 
treatment and genotype effect with the treated Dagla-/-  group compared to untreated Dagla-/-  
group ( p < 0.01) and treated WT group (p < 0.01). Figure 4.3.3C. 
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Figure 4.3.3C: ELISA measurement of OHSC supernatants for cytokine release after 72h LPS 
stimulation. Stimulation with LPS for 72h led to an increase in production of IL1β only in the Dagla-
/-  mice (**p < 0.01) with genotype effect when both stimulated groups were compared (++p < 0.01). 
One-way ANOVA with Bonferroni’s post-hoc test, values represent mean ± SEM; n = 9 per group. 
 
4.4 Effects of increased AEA on microgliosis and microglia morphology 
in the hippocampus during ageing 
 
The endogenous ligands of the endocannabinoid system are the 2-AG and the AEA, whereby, 
2-AG is the main endocannabinoid. Excessive elevation of 2-AG levels or a complete shot 
down of synthesis enzymes, may lead to desensitisation of CB1 and CB2 receptors. Thus, for 
this experiment, we opted for a constitutive FAAH deficient mouse line age 2-3 months (young) 
and 12-15 months (old), where degradation of anandamide is blocked. 
4.4.1 Age- and genotype-dependent increases in microglia density 
 
We wanted to know how ageing and deletion of FAAH influences microglia density in the 
hippocampus. Here, the density of microglia was significantly higher in old than in young 
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animals (age: F1,120 =  44.65; p < 0.001), both in wild-type and FAAH
−/− mice (age × genotype 
interaction F1,120 = 2.588;  p > 0.05). However, we found a significant difference   in the 
microglia density between the genotypes (genotype: F1,120 = 5.043;  p < 0.05). Unexpectedly, 
FAAH−/− animals had a higher microglia density in the hippocampus than wild-type mice. This 
was significant in the young age-group according to Bonferroni's post-hoc test (Figure 
4.4.1A,B) (Adopted and modified from Ativie et al, 2015). 
 
 
Figure 4.4.1: Enhanced microglia density in young FAAH−/− mice. (A) Old animals showed higher 
microglia densities in both genotypes. +p< 0.05 difference between wild type (WT) and FAAH knockout 
mice according to Bonferroni's t-test. **p< 0.01; ***p < 0.001 difference between young and old mice 
according to Bonferroni's t-test. (B) Representative microphotograph of Iba1+ microglial cells in the 
hippocampus. The length of the scale bars is 100 μm (modified from Ativie et al. 2015). 
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4.4.2 Ageing or genetic deletion of FAAH leads to an increase in microglia size  
 
Since the activation of microglia is often characterized by increased cell size, we, therefore, 
wanted to know whether the increased microglia density in ageing due to the deletion of FAAH 
was accompanied by an enhanced ratio of microglia with increased cell sizes. Microglia sizes 
significantly increased in ageing (age: F1,893 = 32.36;  p <0.001), and  this age-related increase 
was  not influenced by the genotype of the animals (age × genotype interaction F1,893  = 2.167;  
p>0.05). Genotype of the mice also had a significant effect on the sizes of microglia (genotype: 
F1,893 = 27.70;  p < 0.001). Post hoc analysis of the data with Bonferroni's t-test revealed that 
the microglia sizes were significantly higher in FAAH−/−   animals in both age groups (Figure 
4.4.2) (Adopted and modified from Ativie et al, 2015) 
 
Figure 4.4.2: Enhanced microglia size in young and old FAAH−/− mice. Old animals showed higher 
microglia sizes in both genotypes. +++p < 0.001 difference between wild- type (WT) and FAAH−/−  mice 
according to Bonferroni's t-test. ***p < 0.001 difference between young and old mice according to 
Bonferroni's t-test. (Modified from Ativie et al. 2015). 
 
4.4.3 Altered cytokine levels in FAAH mice 
 
Next, we wanted to know whether the larger cell bodies – morphological sign of activation – 
were accompanied by enhanced levels of pro-inflammatory cytokines.  For this purpose, we 
measured the concentrations of IL-1β and IL-6. We found a significant main effect of genotype 
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and  age on the concentration of IL-1β (genotype: F1,22  = 12.10;  p < 0.01;  age:  F1,22  =11.31;  
p < 0.01) as well  as a significant age  × genotype interaction (F1,22  = 6.065;  p < 0.05). Post 
hoc analysis of the data revealed that IL-1β levels in young FAAH−/− mice were significantly 
higher as compared to young wild-type animals. Moreover, the age-related increase was 
significant in the wild-type, but not in the FAAH−/−   mice (Figure 4.4.3A). We also found a 
significant main age effect for the IL-6 concentration (F1,23  = 10.32;  p  <  0.01). The genotype 
effect or age × genotype interaction was not significant, (F 1,23  = 1.855; p > 0.05) and  (F1,23  = 
0.8549; p > 0.05) respectively. However, post hoc analysis of the data revealed that the age-
related increase in IL-6 level was only significant in wild type but not in FAAH−/− mice (Figure 
4.4.3B). 
Figure 4.4.3: (A) Hippocampal IL-1β levels were higher in young FAAH−/− than in age-matched wild-
type mice. Age-related increase in IL-1β levels was present in wild-type but not in FAAH−/− mice. (B) 
The elevation in IL-6 levels in ageing reached the level of significance in wild-type but not in FAAH−/− 
mice. +p < 0.05 difference between wild-type (WT) and FAAH knockout mice according to Bonferroni's 
t-test.  **p  <  0.01;  ***p  <  0.001 difference between young and old mice according to Bonferroni's t-
test (Modified from Ativie et al. 2015).
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5. Discussion 
 
Previously published works in our lab have demonstrated that the deletion of CB1 receptor 
results in early onset of brain ageing, marked by memory deficit, enhanced accumulation of the 
ageing pigment lipofuscin, elevated neuroinflammation levels and neuronal loss (Piyanova et 
al. 2013; Bilkei-Gorzo et al. 2005). While these age-related changes were largely restricted to 
the brain, similar age-associated elevation of neuroinflammation was observed after CB1 
receptor was specifically deleted from GABAergic neurons (Albayram et al., 2011).These 
studies taken together indicated that GABAergic neurons play a crucial role in microglial 
activity regulation during ageing and suggested an important role for the endocannabinoid 
system, especially the GABA-CB1 mediated endocannabinoid signalling. In this present study, 
we looked closely into the role played by the GABA-CB1 mediated endocannabinoid signalling 
in the regulation of microglial activity during ageing but also during cases of LPS induced 
pathological conditions in young and old individuals. Additionally, since it is unclear from 
which origin, how and which endocannabinoid (2-AG or anandamide) is involved in the 
observed age-related changes and increased microglial reactivity in the brain, we sought to 
answer these questions employing microglia-specific DAGLα knockout mice as well as 
constitutive FAAH knockout mice in various behavioural, molecular and cellular experiments.  
 
5.1 GABA CB1 deletion leads to enhanced neuroinflammation in ageing 
 
In this study, in reflection on previous results from our lab and literature knowledge 
(Eljaschewitsch et al., 2006), we hypothesized that reduced cannabinoid signalling between 
microglia and the regulatory hippocampal GABAergic neurons would lead to increased 
microglia activity, resulting in enhanced neuroinflammation. Indeed, in a set of experiments in 
organotypic hippocampal slice cultures (OHSCs) with 3 to 5 days old GABA-Cnr1-/-   pups and 
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their wild type littermates, we recorded an increase in production of IL-1β, IL-6 and TNF-α 
levels after lipopolysaccharide (LPS) induced activation of microglia in the organotypic 
hippocampal slices (OHS). This is in line with literature knowledge, as LPS, a Gram-negative 
bacterial endotoxin has been reported to induce a rapid proinflammatory immune innate 
response through Toll-like receptor 4 (TLR4) signalling. Toll-like receptor 4, a pattern 
recognition receptor on immune cells, recognizes pathogen-associated molecular patterns 
(PAMPs) to which LPS is a member (Chakravarty, 2005; Mallard, Wang and Hagberg, 2009; 
Vaure and Liu, 2014). 
 
Figure 5.1A: TLR4 intracellular signalling cascade. The MyD88-dependent pathway induces NF-κB 
translocation and expression of pro-inflammatory cytokine genes. Alternatively, MyD88-independent 
pathway induces NF-κB or IRF3 translocation, leading to expression of pro-inflammatory cytokine 
genes by NF-κB or IFN-β and TNF-α genes by IRF3 (Adapted from Vaure & Liu 2014). 
 
 However, following chronic exposure of microglia/macrophage to LPS, immune cell tolerance 
ensues. LPS and the produced cytokines activate intracellular tyrosine kinases leading to 
modulation of mitogen-activated protein kinase (MAPK) cascade followed by other 
downstream signalling processes. Eventually, proinflammatory cytokine/chemokine release is 
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reduced and the microglia transit from the proinflammatory M1 to repair and regenerative M2 
state, preventing neurotoxicity (Tominaga et al., 1999; Ajmone-Cat, Nicolini and Minghetti, 
2003; Antonietta Ajmone-Cat et al., 2013) . Strikingly, this self-protection mechanism seems 
to be hampered in GABA-Cnr1-/-   mice. We observed that IL-1β, IL-6 and TNF-α levels were 
downregulated to control levels in the WT stimulated groups, while the levels of these 
proinflammatory cytokines remained high in GABA-Cnr1-/-  samples stimulated with LPS. 
These findings indicate a disturbed downregulation of cytokine production in GABA-Cnr1-/- 
samples after a chronic stimulation with LPS. Consequentially, increased neuroinflammation 
as a result of microglia overreactivity can be expected in GABA-Cnr1-/- mice. This implies that 
during chronic pathological conditions in the brain, the modulatory role of the cannabinoid 
system on microglia may be lost in GABA-Cnr1-/- individuals. This may be another explanation 
and a confirmation of exacerbated microglia activity, cognitive decline and other age-associated 
pathologies observed in previous studies with these mice (Albayram et al., 2011; Piyanova et 
al., 2013). We are aware that this experiment may be more representative if slices from older 
mice were included. This was, however, not achievable due to technical limitations. 
Organotypic hippocampal slices from older mice survive only poorly in culture using present 
protocols, necessitating a tenfold increase in the number of animals needed for the study, which 
in turn is not in conformity with existing regulatory modalities concerning studies with 
genetically modified animals. Modification of present protocols, which is proving very difficult 
at the moment, to accommodate adult slices is therefore of utmost interest. Moreover, since the 
cytokine levels were measured in the collected culturing media using ELISA, variations in the 
results from different batches of ELISA experiments are predictable due to variation from 
ELISA plates during plate-reading. A possible solution to this issue is to collect all samples 
overtime and then perform ELISA, distributing the samples evenly in the plates to reduce plate 
variation. The down side to this approach is, however, that one may have to collect and store 
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the samples for a longer period of time, which in turn could lead to degradation of the cytokines 
in the sample-medium. 
In a further study, we evaluated the effect of CB1 deletion from GABAergic neurons on 
microglia activity in situ. Here, 2 months old GABA-Cnr1-/- mice and their wild type littermates 
were intraperitoneally injected with 0.8mg/kg LPS or saline as control. In order to mimic a 
broader spectrum of pathological conditions in the brain, which is usually chronic with 
microglia exposed to the activating stimulant for a prolonged period of time, we set out to 
administer LPS to the mice once which represents an acute stimulation (single injection) or on 
four consecutive days (multiple stimulation), representing a chronic stimulation (Ajmone-Cat, 
Nicolini and Minghetti, 2003). As expected, hippocampal microglia density was increased in 
treated mice with no particular correlation to genotype, though it appears that CB1 deletion on 
GABAergic neurons already showed tendencies of increased microglia density. Indeed, this is 
an interesting observation, as previous experiments from our lab show that in older mice 
microglia density in the hippocampus is increased in 12 months old  GABA-Cnr1-/- mice as 
compared to 2 months old mice (Albayram et al., 2011). This suggests that microglia activity 
increases in GABA-Cnr1-/- mice with increasing age, ultimately leading to microglial 
overreactivity and neuronal loss reported in old GABA-Cnr1-/- mice. Equally notable is the 
exacerbated microglia density in the multiple injected mice when compared to single injected 
individuals. Here, multiple LPS injection led to a much stronger response in the GABA-Cnr1-/- 
mice, indicating that these mice are more vulnerable to endotoxins.  Literature knowledge has 
it, that levels of some prominent cytokines like IL-6, IL-1β and TNF-α are increased in older 
GABA-Cnr1-/- mice (Albayram et al. 2011). It is remarkable, therefore, that this present work 
shows that the increased cytokine level is not present in younger GABA-Cnr1-/- mice as 
cytokine levels were similar in both knockout and WT without LPS treatment and equally 
increased after LPS treatment. This is true for IL-1β and TNF-α in both single and multiple 
injection paradigms. However, the magnitude of increase of these cytokines was lower in the 
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multiple injection paradigm in accordance with literature (Ajmone-Cat, Nicolini and Minghetti, 
2003; Antonietta Ajmone-Cat et al., 2013).  A decreased IL-6 expression was recorded after 
single injection and levels were unchanged in multiple injection paradigm for both genotypes. 
This observation also depicts literature knowledge as it has been reported that TNF and IL-6 
are the first line of  cytokines released after LPS stimulation of blood samples with IL-6 level 
returning back to very low concentration after 6 hours while TNF also returned to low level but 
was after 24 hours still 70 fold higher than IL-6 concentration (DeForge and Remick, 1991). 
This may explain the erratic results obtained with IL-6, indicating that we would have had to 
sacrifice the mice 4 to 6 hours after injection to catch actual IL-6 expression levels and not after 
24 hours as we did. It is important to keep in mind that the size of LPS prevents LPS from easily 
crossing the blood brain barrier (Singh and Jiang, 2004). Hence, unlike stimulation in cell 
culture, organotypic hippocampal slice culture or intracerebroventricular (ICV) injection where 
LPS acting as an agonist can directly trigger TLR4 signalling in microglia, LPS administered 
intraperitoneally binds to TLR4 receptors on peripheral immune cells to orchestrate production 
of cytokines and other immune mediators that cross the blood brain barrier to activate microglia. 
Thus, a slight discrepancy in microglia response may occur depending on the mode of 
activation. The outcome of this set of experiments with reference to literature (Albayram et al., 
2011), confirms that CB1 knockout from GABAergic neurons unfolds its detrimental 
consequences with increasing age.  
In another set of experiments, microglial reactivity was assessed in 3 age groups of GABA-
Cnr1-/- mice and age-matched WT littermates. This time, however, LPS stimulation was 
administered bilaterally into the hippocampus. This represents a direct and acute activation of 
microglia, unlike in the intraperitoneal injection experiments where microglia are indirectly 
activated through the response from peripheral immune cells. Employing social preference test, 
we were able to deduce sickness behaviour in mice treated with LPS as compared to those 
treated with artificial cerebrospinal fluid (ACSF) in all age and genotype groups. Treated mice 
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showed reduced motility and sociability as they interacted less with partner mice, which is a 
typical response to infection in animals  (Fisch, 2007; Nestler and Hyman, 2010). In cases of 
infection, animals change their behaviour to support physiological and metabolic conditions in 
the body. The phenotypic consequences of this process are expressed in reduced activity and 
interest alongside with responses like increased body temperature (Aubert, 1999; Wynne, 
Henry and Godbout, 2009). Although the sickness behaviour in WT mice was evidently strong 
across all age groups, in GABA-Cnr1-/- mice the sickness behaviour was exacerbated with 
increasing age. This finding is again in agreement with observations that CB1 receptor knockout 
becomes detrimental in ageing as evident in recorded increase in microglial reactivity in old 
GABA-Cnr1-/- mice  (Albayram et al., 2011; Piyanova et al., 2013). And indeed, the density of 
microglia in the hippocampus of treated 18 months old GABA-Cnr1-/- mice was much higher 
than in the treated WT mice. In addition younger untreated GABA-Cnr1-/- mice always had 
more microglia in their hippocampus than the untreated WT. This is also in line with previously 
reported increase microgliosis in young GABA-Cnr1-/- mice. Nonetheless, it is safe to say that 
the increase in microglia density in young GABA-Cnr1-/- mice did not lead to exacerbated 
sickness behaviour, opening the question of the profile of these microglia. Strikingly, 
expression of IL-1β and TNF-α was similarly increased in WT mice after LPS treatment across 
all age groups. On the contrary, these cytokines increased in treated GABA-Cnr1-/- mice in an 
age-dependent manner. Although there are no morphological experiments to back this claim, 
one may argue that the predominant number of microglia in the young GABA-Cnr1-/- mice are 
of the M2 polarization with less detrimental effect on the brain (Chhor et al., 2013). Yet, IL-6 
expression was unstable as previously observed and possible reasons for this has been 
discussed. 
Accumulation of lipofuscin has been reported to be accelerated in constitutive CB1 receptor 
knockout mice (Piyanova et al., 2013) and accumulation of these lipopigments is wildly 
accepted as an ageing-marker, resulting from increasing dysfunction of cellular clearance 
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mechanisms (Brunk and Terman, 2002; Terman and Brunk, 2004). In most studies, lipofuscin 
content of the cells is examined in fixed brain sections. Lipofuscin is, however, present in 
virtually all cell types in the brain including neurons, though at a much lower amount compared 
to glial cells that account for  80 to 90 % of total lipofuscin in the brain  (Riga et al., 2006). In 
this experiment isolated microglia from young and old GABA-Cnr1-/- mice with their age-
matched littermates were analyzed for lipofuscin content by fluorescence activated cell sorting 
(FACS). Mirroring previous findings, CB1 knockout from GABAergic neurons alone sufficed 
to elicit accelerated lipofuscin accumulation in microglia from old animals. This implies that 
microglia population in older GABA-Cnr1-/- mice contain far more dysfunctional microglia 
than their age-matched WT littermates. Consequentially, microglia in these mice can be 
overreactive, thereby harming neighbouring cells which ultimately contributes to accelerated 
brain ageing.  
5.2 Reduced microglial 2-AG production leads to altered neuron-
microglia interaction 
 
A reduced endocannabinoid signalling, resulting from reduced cannabinoid receptor expression 
(Canas et al., 2009) and coupling to Gi proteins (Wang et al., 2003; Feliszek, 2016) and lower 
2-AG levels due to diminished Daglα activity (Piyanova, 2016) has been described in the ageing 
brain. Moreover, a reduced endocannabinoid production has been linked to a disturbed neuron-
microglial bidirectional communication via neuroimmune regulator protein pairs such as the 
CD200-CD200R and CX3CL1-CX3CR1 (Hernangomez et al., 2012; Justin et al., 2012; Wong, 
2013), leading to increased inflammation and accelerated brain ageing alongside with 
characteristics of various neurodegenerative diseases (Zhang et al., 2011). Expectedly, 
expression of these neuroimmune regulator proteins is reduced in ageing (Jurgens and Johnson, 
2012).  In addition, unpublished findings in our lab indicated that while expression of CD200 
and CD200R is reduced in the hippocampus of ageing mice both in wild type and GABA-Cnr1-
/-, old GABA-Cnr1-/-  animals expressed higher levels of this protein pair compared to age-
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matched wild type littermates. This present study showed a significant decrease or a tendential 
decrease in the expression of both regulator protein pairs (CD200-CD200R and CX3CL1-
CX3CR1) in older mice irrespective of genotype.  This is in line with literature as expression 
of these protein pairs have been reported to reduce during ageing. Interestingly, however, the 
observed decrease in expression levels of these protein pairs was less pronounced in old 
microglia-specific Daglα knockout mice compared to their age-match wild type littermates. 
This observation mirrors our findings in GABA-Cnr1-/-  animals, though only in the CD200-
CD200R protein pairs, where expression levels were higher in old knockout mice as compared 
to wild type in similar age. Now, the outcome of this study may appear inconsistent or even 
contradictory to the overall consequences of reduced or disturbed cannabinoid signalling 
observed so far, since these neuroimmune regulator proteins have been shown to be reduced in 
ageing and various CNS pathologies. On a second look, the results are consistent with literature 
as expression of these protein pairs is generally reduced in both old WT and knockout mice, 
but with an additional information that a compensatory effect attempt in response to reduced 
cannabinoid signalling may be induced via direct neuron-microglia interaction. The purpose of 
this likely compensatory response could be to offset microglia overreactivity resulting from 
altered cannabinoid signalling. Indeed, a further experiment with these microglia-specific 
Daglα knockout mice showed that some genes encoding GABA A receptor subunits are 
upregulated in microglia isolated from old Dagla-/- mice when compared to old wild type mice, 
while cytokine production was also increased. A possible reason for the observed expression 
change can either be due to increased production of GABA A receptors or change in its 
composition in the microglia.   These findings taken together elude to the importance of the 
endocannabinoid signalling in the bidirectional regulation of neurons and microglia and 
ultimately in the regulation of microglia reactivity during ageing. 
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5. 3 Cognitive ageing and microglial reactivity in microglia-specific 
Dagla-/- mice 
 
In this set of experiments, the consequences of a reduced 2-AG production on age-related 
changes in learning ability were investigated in partner and object recognition tests. A 
longitudinal study of microglia-specific Dagla-/- male mice and their age-matched wild type 
littermates revealed that sociability was similarly strong in all tested mice irrespective of age 
and genotype. Although we expected both young and old mice to show a significantly higher 
preference for conspecific partner mice as compared to an object, it was also important to 
exclude its influence on partner recognition because a normal sociability is a prerequisite for 
partner recognition. As expected, young and older knockout mice displayed a strong preference 
for partner mice similar to performances obtained with wild type mice without any age 
difference. Moreover, the recognition strength seemed to be reduced in older Dagla-/-  mice as 
compared to young Dagla-/-  mice. Although no significant recognition ability was obtained with 
young wild type mice, we, however, think that this must be due to some experimental failures 
or mistake on the part of the experimenter. Nonetheless, the slightly better performance, at least 
in the young Dagla-/-  mice, is consistent with literature knowledge on the effect of reduced 
cannabinoid signalling in younger mice, as young CB1 knockout mice were reported to have a 
superior recognition ability compared to age-matched wild type mice (Bilkei-Gorzo et al., 
2005). Also consistent with literature is the intertrial interval dependent decrease in recognition 
ability in old mice with disturbed cannabinoid signalling (Bilkei-Gorzo et al., 2005, 2012). 
Male microglia-specific Dagla-/-  mice showed a weaker recognition for previously seen mice 
compared to age-matched wild type mice after 2 hours intertrial interval. Whereas there was no 
difference in the recognition ability after 30 minutes and 1 hour intertrial intervals. These 
results, in line with previous publications from our lab, suggest that reduced cannabinoid 
signalling leads to memory deficit, especially in aged mice. Although not as strong as in CB1 
knockout mice, it is interesting that Daglα knock on microglia is enough to show tendencies of 
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memory deficits in old mice. As intended, if these mice are tested again at a much older age (18 
months or older), these tendencies are likely to become even stronger and clearer, reflecting 
previous findings (Bilkei-Gorzo et al., 2005, 2012). Male mice were solely used throughout 
this longitudinal object and partner recognition experiments. Female animals are often excluded 
from behavioural experiments with reference to hormonal fluctuation occurring during the 
estrous cycle that may influence female mice performance in such tests (Mogil et al., 2000). 
The performance of female animals in object recognition test has been reported to be highly 
inconsistent depending on the phase of estrous cycle the animals are currently in (van Goethem 
et al., 2012). Although female black 6 mice (C57BL/6J)  have been reported to be less affected 
by the estrous cycle in various behavioural tests (Meziane et al., 2007), their performances in 
recognition tests are yet unstable owing to previous experience in our lab.  
In a parallel longitudinal study with female microglia-specific Dagla-/-  mice and wild type 
littermates, the spatial learning and memory abilities of mice were assessed in the Morris water 
maze (MWM) test. It has been previously reported that a disturbance of the endocannabinoid 
signalling as a result of a constitutive deletion of CB1 receptor led to age-related learning and 
memory deficits (Albayram et al., 2011). Regrettably, in this study, perturbation in the 
endocannabinoid system through a reduced 2-AG production as a consequence of Daglα 
deletion on microglia did not result in learning and/or memory deficits neither in the young nor 
in the old mice regardless of genotype.  Although we have shown that reduced 2-AG production 
leads to an altered neuron-microglia crosstalk, the results indicated more of a compensation 
effect than a detrimental effect. Hence it is possible that the reduction in 2-AG achieved by 
deletion of Daglα specifically from microglia is not strong enough to provoke microglial 
overreactivity that in turn would lead to neuronal loss and the associated learning and memory 
deficits in our 2 months old mice and just about sufficient to elicit a worsened performance in 
12 months old mice. Besides, the main producers of 2-AG in the brain is not established, though 
this is ascribed mainly to neurons and astrocytes are well capable of producing 
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endocannabinoids. Thus, reduction in microglial 2-AG production may alter microglia 
activation, but may not be sufficient to significantly affect the overall signalling of the 
cannabinoid system in the brain. Moreover, the MWM test is extremely dependent on 
hippocampal functioning (Kenney and Gould, 2009). Hence, if there is no increased 
neuroinflammation in the hippocampus as is the case in old CB1 receptor knockout mice 
(Albayram et al., 2011; Piyanova et al., 2013), cognitive deficits may be unlikely. Nonetheless, 
we observed an age-dependent loss of memory strength in the older mice, irrespective of 
genotype. This is in line with literature, as animals tend to have a weakening memory strength 
with increasing age. These results taken together suggest that reduction in 2-AG production in 
microglia may not be sufficient to elicit cognitive deficits, at least in 12 month old mice. Since 
it is a longitudinal test and the mice will be tested again when they are much older, there is a 
chance that the conclusion of this study at this stage might change. Lastly, the MWM test is an 
aversive test that could influence animal behaviour. In order to reduce this possible source of 
inconsistency, we used only female mice in the MWM test. Female animals have been reported 
to be less affected by acute stress-related impairment in spatial memory (Conrad et al., 2004). 
Although Daglα deletion from microglia did not lead to a significant impairment in the 
cognitive and social ability of tested mice as at 12 months old, we, however, yet sought to 
investigate any possible changes in microglial reactivity, ensuing from a reduced cannabinoid 
signalling. In a set of OHSC experiments, we demonstrated that the deletion of Daglα from 
microglia alone resulted in an increase in cytokines production similar to levels obtainable in 
both WT and microglia-specific Dagla-/-  mice stimulated with LPS for 24 hours. A similar 
pattern was also observed with TNFα production in the GABA-Cnr1-/- mice. Interestingly, LPS 
stimulation did not seem to further exacerbate cytokines production in Dagla-/-  mice in the first 
2 days of the experiments, while LPS stimulation clearly raised cytokines production in the WT 
samples. As expected and in line with literature (Ajmone-Cat, Nicolini and Minghetti, 2003; 
Antonietta Ajmone-Cat et al., 2013), cytokine release was eventually reduced to WT 
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unstimulated levels after 3 days. Strikingly, this time, unstimulated Dagla-/-  samples, wherein 
cytokine levels was previously high, was also now downregulated. Only in IL-1β production 
was an LPS and genotype effect sustained in stimulated Dagla-/-  samples. Even though these 
results point to a slightly dysregulated cytokines production in the Dagla-/-  mice, this cannot be 
a clear-cut conclusion as was the case with results obtained from experiments with GABA-
Cnr1-/- mice. Moreover, unpublished findings in our lab also showed that LPS intraperitoneally 
injected into microglia-specific Dagla-/-  mice led to changes in cytokines expression that were 
similar to those obtained in their LPS-treated WT littermates. All in all, we may conclude that 
microglia-specific Daglα deletion only mildly if at all affects microglial reactivity.  
5.4 Enhanced anandamide (AEA) levels lead to microgliosis and changes 
in microglial morphology in the hippocampus during ageing 
 
In this set of experiments, we investigated the effects of increased AEA on microglia activity 
in FAAH -/-  mice alongside the possible age-associated consequences.  Now, it is crucial to 
note that an anti-inflammatory effect of AEA on microglia has been reported after activation 
with LPS (Facchinetti et al., 2003; Tham et al., 2007). Furthermore, a  neuroprotective effect 
was demonstrated in hippocampal slice culture after  NMDA treatment (Eljaschewitsch et al., 
2006). In addition, enhanced AEA levels has proven to be protective in a viral model of multiple 
sclerosis (Correa et al., 2011) and in traumatic brain injury (Tchantchou et al., 2015). However, 
findings in this study revealed an increase in the density and size of microglia both in wild-type 
and  FAAH-/-   mice in ageing.  Importantly, the density of microglia was higher in the FAAH-
/-  mice as compared to wild- type animals in the young 2 months old age group. This increased 
microgliosis mirrors the trend observed in previous work, as a disturbance in the cannabinoid 
signalling often results in increased microgliosis already at an early age even though not always 
accompanied with pathological consequences. Furthermore, a larger microglia size was 
recorded in the FAAH-/-  mice as compared to wild-type in both 2 and 12 months old mice. 
Moreover, we demonstrated that ageing led to an increased expression of two prominent pro- 
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inflammatory cytokines; IL-1β and  IL-6 in wild-type mice. Interestingly,  this age- related 
increase was totally absent (IL-1β) or failed to reach the level of significance (IL-6) in FAAH-
/-  mice.  Again and importantly, IL-1β level was already high in young FAAH-/- mice, which 
may suggest higher inflammation. We have previously argued that IL-6 is rapidly degraded 
after production (DeForge and Remick, 1991), preventing accurate detection of the actual level 
of expression if samples were collected later than 4 hours after induction of release. This 
argument, however, does not hold here as the deletion of FAAH continues to have effect and 
the samples were not additionally treated with any stimulant like LPS. Hence,  a possible reason 
why IL-1β and IL-6 are differently affected by FAAH could be that IL-1β is secreted through 
a non-classical export mechanism, whereas IL-6 through the classical mechanism (Eder, 2009). 
So, it is conceivable that anandamide differentially affects these secretory pathways.  
Alternatively, since  IL-1β and  IL-6 are produced in a premature form, it is also possible that 
anandamide differentially affects their maturation process (Akdis et al., 2011).Taken together, 
these changes are indicative of a more pronounced pro- inflammatory activity state of microglia 
in young FAAH-/-  mice.  Therefore, it can be concluded from these results that increased AEA 
levels due to the genetic deletion of FAAH leads to pro-inflammatory changes in the brain of 
young animals and these changes are akin to those observed during the normal ageing process. 
Consequentially, it is evident that a balance in endocannabinoid levels is essential for proper 
functioning of the endocannabinoid system, while excessive or reduced production of 
endocannabinoids may prove detrimental.  Although the implications of FAAH deletion 
inferable from our experiment does not entirely replicate literature knowledge, one can argue 
that our work may not be completely comparable to other studies where an acute stimulation 
with LPS or brain injury was employed. In normal ageing, a pro-inflammatory milieu develops 
slowly over an extended period of time and the neuroinflammation is weaker than under most 
pathological conditions. Thus, it is possible that AEA blocks the acute induction of 
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inflammatory processes after a strong trigger, whereas it does not counteract slowly progressing 
pro-inflammatory changes. (Adapted and modified from Ativie et al. 2015).  
 
5.5 Conclusion and outlook 
 
The crucial role of microglia in host-defence against pathogens in the brain and the 
consequences of microglial overreactivity in the initiation and progression of 
neuroinflammatory processes are well established. Furthermore, the importance of neuron-
microglial bidirectional regulation in maintenance of homeostasis in the CNS especially during 
ageing and the role of the endocannabinoid system are all reinforced by a body of growing 
evidence. In addition, the importance of CB1 receptor activity and GABA-CB1 receptor activity 
in supporting a balance between pro- and anti-inflammatory processes in the ageing brain has 
been reported. This present work further strengthens the aforementioned findings and provides 
a better understanding of which particular cell types and how the endocannabinoid signalling 
may be involved in the regulation of   “normal” brain ageing process as well as in pathological 
processes. This study has shown that GABA-CB1 mediated endocannabinoid signalling is 
indispensable for a healthy brain ageing. We established that the reported downregulation of 
proinflammatory cytokines after an insult to the brain which is important to prevent damage to 
cells in the CNS especially neurons is disturbed in GABA-CB1 knockout mice. Furthermore, 
we showed that microgliosis and proinflammatory cytokines are slightly higher in GABA-CB1 
receptor knockout individuals and become worsened after treatment with LPS in aged mice. 
This implies that pathological conditions are exacerbated in mice lacking GABA-CB1 
receptors, particularly during ageing. Moreover, we demonstrated an increased accumulation 
of lipofuscin in microglia of old GABA-CB1 knockout mice, indicating an exacerbated 
senescent property in microglia and so with accelerated ageing in these mice. However, these 
changes did not result in heightened sickness behaviour or cognitive deficits distinct to the 
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GABA-CB1 knockout mice. This study also showed that a reduced 2-AG level leads to 
upregulation of direct neuron-microglial communication proteins during ageing, suggesting a 
compensation attempt for reduced cannabinoid signalling. Nevertheless, a reduced 2-AG level 
and the observed upregulation in neuroimmune regulator proteins were not accompanied by 
significant social or cognitive deficits in mice lacking Daglα.  Although, reduced 2-AG level 
did not affect microglial activity in every case, increased AEA led to increased microgliosis 
and microglia activity irrespective of age.  Now, with the exception of behavioural experiments, 
this study has shown that the genetic deletion of CB1 receptors on GABAergic neurons was 
sufficient to replicate findings reported in constitutive CB1 knockout mice, underlining the 
importance of GABAergic neurons in the regulation of microglial activity in the ageing and 
diseased brain. Nonetheless, further experiments most now focus on the dynamics of 
epigenetics and gene expression profile in these mice and the role of astrocytes should be looked 
into. The longitudinal behavioural experiments that are still ongoing should continue at least 
till mice are 24 months old. There is a good chance that the effect of reduced 2-AG level is only 
achievable at a much-advanced age. 
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